Heteroaryl derivatives and uses thereof

By designing heteroaryl derivatives represented by formula (I), the problem of inconsistent efficacy of existing HER2 inhibitors in the treatment of HER2-mutant cancers has been solved, achieving potent inhibition of HER2 and making it suitable for the treatment of a variety of HER2-related diseases.

CN118946557APending Publication Date: 2024-11-12VORONOI INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030419.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-05
Filing Date
2023-04-05
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing HER2 inhibitors exhibit cancer-specific and variant-specific differences in the treatment of HER2-mutant cancers, necessitating the development of new compounds to effectively inhibit HER2 and treat related diseases.

Method used

A heteroaryl derivative represented by formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof is provided, which achieves excellent inhibitory activity against HER2 through specific structural design.

Benefits of technology

This compound exhibits potent inhibitory activity against HER2 and can be used to treat HER2-related diseases, especially cancer, with broad therapeutic and preventative effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005059726410000021
    Figure BDA0005059726410000021
  • Figure BDA0005059726410000067
    Figure BDA0005059726410000067
  • Figure BDA0005059726410000082
    Figure BDA0005059726410000082
Patent Text Reader

Abstract

The invention relates to heteroaryl derivatives and uses thereof. The heteroaryl derivative represented by chemical formula (I) and the pharmaceutical composition comprising the heteroaryl derivative effectively inhibit HER2 activity, and thus can be used for treating or preventing HER2-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to heteroaryl derivatives and their pharmaceutical uses. Specifically, the present invention relates to heteroaryl derivatives having HER2 inhibitory activity.

[0002] The research for the present invention was carried out with the support of the National Drug Development Project (Project ID: HN21C0826) of the Korea Drug Development Foundation funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare. Background Art

[0003] Human epidermal growth factor receptor 2 (HER2) is a member of the human EGFR family, and it is known that abnormal expression or activity of HER2 is the main cause of various cancers (e.g., breast cancer, lung cancer, gastric cancer and ovarian cancer) (J Control Release, 2010, 146 (3), 264-275). In particular, amplification of the HER2 gene or overexpression of HER2 protein is observed in about 15% to 25% of breast cancer patients, which is classified as HER2-positive. Cancer is caused by various mutations of wild-type HER2 and HER2, such as L755S, V777L, D769H / Y, T862A and L755_T759del in the kinase domain are known.

[0004] Herceptin TM ) and Perjeta TM ) are representative HER2 monoclonal antibodies that inhibit the HER2 signal transduction mechanism and are therefore used as therapeutic agents for breast cancer, and it is reported that they improve clinical outcomes compared to chemotherapy alone (Journal of Clinical Oncology, 2002, 20(3), 719-726). Antibody-drug conjugates (ADCs) made by connecting cytotoxic drugs and HER2 selective antibodies are also developed as related therapeutic agents, as drugs such as lapatinib (Tykerb TM ) and tucatinib (Tukysa TM ) have been developed and used as a breast cancer therapeutic.

[0005] In phase 1 and 2 clinical trial data, patients with HER2 mutations were reported to respond to the HER2 inhibitor afatinib (Gilotrif TM ), Neratinib (Nerlynx TM ) or dacomitinib (Vizimpro TM) had a partial response (Annals of Oncology, 2015, 26 (7), 1421-1427). Specifically, the SUMMIT clinical trial reported an objective response rate (ORR) of 24% for patients with HER2 mutant breast cancer and 3.8% for patients with HER2 mutant lung cancer, while other cancers with HER2 mutations were 0% (Nature, 2018, 554 (7691), 189-194). However, different ORR results were found according to the disease, indicating that the efficacy of HER2 inhibition is cancer-specific and that there are also variant-specific differences in a single cancer (Nature, 2018, 554 (7691), 189-194). Studies on HER2 monoclonal antibodies and antibody-drug conjugates (ADCs) have also found similar results as above, showing different ORRs depending on the type of mutation. This suggests that there is still a need to prevent or treat various HER2 mutations.

[0006] [Prior art literature]

[0007] (Non-patent document 1) J Control Release, 2010, 146(3), 264-275

[0008] (Non-patent document 2) Journal of Clinical Oncology, 2002, 20(3), 719-726

[0009] (Non-patent document 3) Annals of Oncology, 2015, 26(7), 1421-1427

[0010] (Non-patent document 4) Nature, 2018, 554(7691), 189-194. Summary of the invention

[0011] Technical issues

[0012] As a result of extensive efforts to develop new drugs, the present inventors have found that the compounds of the present invention effectively inhibit HER2 and thus have therapeutic and preventive effects on HER2-related diseases, thereby completing the present invention.

[0013] Therefore, an object of the present invention is to provide novel heteroaryl derivatives or pharmaceutically acceptable salts or stereoisomers thereof, and methods for preparing them.

[0014] Another object of the present invention is to provide a pharmaceutical use of a heteroaryl derivative or a pharmaceutically acceptable salt or stereoisomer thereof.

[0015] Solution to the problem

[0016] In accordance with the above object, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof.

[0017]

[0018] wherein ring A, X1, X2, Y1, Y2, Y3, L and Z are the same as defined in the present specification.

[0019] Advantageous Effects of the Invention

[0020] The compound represented by formula (I), its stereoisomer or its pharmaceutically acceptable salt can show excellent inhibitory activity to HER2. Therefore, the compound of the present invention can be used as a HER2 inhibitor, and the pharmaceutical composition comprising the compound can be used as a therapeutic agent for HER2-related diseases, particularly cancer.

[0021] Best Mode for Carrying Out the Invention

[0022] Hereinafter, the present invention will be described in more detail.

[0023] Embodiments of the present invention can be modified in different forms, and the scope of the present invention is not limited to the embodiments described below. Embodiments of the present invention are also provided to more fully illustrate the present invention to those skilled in the art. In addition, throughout the specification, the part of "comprising" components means that it can further include other components, rather than excluding other components, unless otherwise stated.

[0024] In the present specification, the term "halo" or "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I), unless otherwise specified.

[0025] The term "alkyl" refers to a radical obtained by removing one hydrogen from a straight or branched chain saturated hydrocarbon radical, unless otherwise indicated. For example, "C 1-10 "Alkyl" refers to an alkyl group having a skeleton formed by 1 to 10 carbon atoms. Specifically, C 1-10 The alkyl group may include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, tert-pentyl, sec-pentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, and the like.

[0026] The term "alkoxy" refers to an alkyl group linked by -O-, for example, C 1-4 The alkoxy group may include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, etc., but is not limited thereto.

[0027] The term "alkylamino" refers to an amino group substituted with one or two alkyl groups. 1-6 Alkylamino may be a1-6 Alkyl-substituted amino groups, i.e. -NH(C 1-6 Alkyl) or -N(C 1-6 The alkyl) 2 may include dimethylamino, diethylamino, methylethylamino, methylpropylamino and ethylpropylamino, but is not limited thereto.

[0028] The term "hydroxyalkyl" refers to a straight or branched alkyl group having a carbon atom substituted by a hydroxyl group (-OH), and includes, for example, methyl, ethyl, propyl, isopropyl, isobutyl and n-butyl substituted by a hydroxyl group, but is not limited thereto. Similarly, "hydroxyalkoxy" refers to a straight or branched alkoxy group having a carbon atom substituted by a hydroxyl group (-OH).

[0029] The term "haloalkyl" refers to a straight or branched chain alkyl group having carbon atoms substituted by one or more halogens (F, Cl, Br and I). Examples of haloalkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl and n-butyl substituted by one or more halogens.

[0030] The term "deuterated" means that at least one hydrogen atom (H) present in a hydrocarbon group is replaced by a deuterium atom (D). As a specific example, deuterated C 1-6 Alkyl means C 1-6 At least one hydrogen atom bonded to a carbon atom in the alkyl group is substituted with a deuterium atom.

[0031] The term "carbocycle" refers to an aromatic or non-aromatic hydrocarbon ring, which may be saturated or unsaturated and may include monocyclic or polycyclic rings. For example, the term "C 3-10 A "carbocycle" refers to a carbon ring having a skeleton formed by 3 to 10 carbon atoms and may have one or more substituents. Depending on the number of carbon atoms constituting the ring, the carbocycle may include, but is not limited to, C 3-15 Carbon ring, C 3-10 Carbon ring, C 3-7 Carbon ring, C 6-12 In a specific example, the aromatic C 6-10 Carbocyclic rings include benzene and naphthalene.

[0032] The term "cycloalkyl" refers to a non-aromatic hydrocarbon ring group, which may include a monocyclic or polycyclic ring. Cycloalkyl may include a saturated ring, and specific examples thereof may include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, etc. In addition, cycloalkyl may include an unsaturated ring having one or more carbon-carbon double bonds in the ring, as long as the ring does not become aromatic due to the presence of the double bond, such as cyclopentenyl, etc. may also be included in this category. Depending on the number of carbon atoms constituting the ring, cycloalkyl may include, but is not limited to, C 3-14 Cycloalkyl, C 3-12 Cycloalkyl, C 3-10 Cycloalkyl, C 3-6Cycloalkyl, C 6-12 Cycloalkyl, etc.

[0033] The term "aryl" refers to an aromatic hydrocarbon ring group, which may include a monocyclic or polycyclic ring. Specific examples of aryl groups may include, but are not limited to, phenyl, naphthyl, fluorenyl, anthracenyl, phenanthrenyl, biphenyl, terphenyl, and the like. In addition, for aryl groups, any hydrocarbon ring group having at least one ring as follows: the electrons in the ring are delocalized due to alternating single and double bonds (i.e., conjugated π bonds) may be included in this category. Depending on the number of carbon atoms constituting the ring, aryl groups may include, but are not limited to, C 6-12 Aryl, C 6-10 Aryl, etc.

[0034] The term "polycyclic" is at least bicyclic, and includes spiro, fused or condensed rings, or bridged rings.

[0035] The term "heterocycle" refers to an aromatic or non-aromatic ring having one or more heteroatoms, which may be saturated or unsaturated, and may include monocyclic or polycyclic rings. For example, a "5- to 12-membered heterocycle" refers to a heterocycle having a skeleton formed by a total of 5 to 12 atoms including heteroatoms and carbon atoms, and may have one or more substituents. Depending on the number of atoms constituting the ring, the heterocycle may include, but is not limited to, a 5- to 12-membered heterocycle, a 5- to 10-membered heterocycle, a 5- to 7-membered heterocycle, and the like.

[0036] The term "heteroaryl" refers to an aromatic heterocyclic group having one or more heteroatoms in the ring, which may include a monocyclic or polycyclic ring. A heteroaryl group may be a group in which one hydrogen atom is removed from an aromatic heterocyclic ring such as thiophene, purine, pyrrole, pyrazole, imidazole, thiazole, oxazole, isothiazole, oxadiazole, triazole, pyridine, bipyridine, triazine, acridine, pyridazine, pyrazine, quinoline, quinazoline, quinoxaline, phenoxazine, phthalazine, pyrimidine, pyridopyrimidine, pyridopyrazine, pyrazinopyrazine, isoquinoline, indole, carbazole, imidazopyridazine, imidazopyridine, imidazopyrimidine, Pyrazolopyrimidine, imidazopyrazine, pyrazolopyridine, triazolopyridine, triazolopyridine, N-arylcarbazole, N-heteroarylcarbazole, N-alkylcarbazole, benzoxazole, benzimidazole, benzothiazole, benzocarbazole, benzothiophene, dibenzothiophene, thienothiophene, benzofuran, phenanthroline, isoxazole, oxadiazole, thiadiazole, benzothiazole, tetrazole, phenothiazine, dibenzosilole, dibenzofuran, pyrazolopyridine, etc., but are not limited thereto. In addition, for heteroaryl, any heterocyclic group having at least one ring in which the electrons in the ring are delocalized due to alternating single bonds and double bonds (i.e., conjugated π bonds). Furthermore, the heteroaryl group may include, but is not limited to, a 5- to 14-membered heteroaryl group, a 5- to 10-membered heteroaryl group, a 5- to 6-membered heteroaryl group, a 6- to 12-membered heteroaryl group, a 6- to 10-membered heteroaryl group, and the like, depending on the number of atoms constituting the ring.

[0037] The term "heterocycloalkyl" refers to a non-aromatic heterocyclic group having one or more heteroatoms in the ring, which may include monocyclic or polycyclic rings. Heterocycloalkyl may include saturated rings. In addition, heterocycloalkyl may have one or more carbon-carbon double bonds or carbon-heteroatom double bonds in the ring, as long as the ring does not become aromatic due to the presence of double bonds. Depending on the number of atoms constituting the ring, heterocycloalkyl may include, but is not limited to, 3 to 15-membered heterocycloalkyl, 3 to 12-membered heterocycloalkyl, 4 to 10-membered heterocycloalkyl, 4 to 8-membered heterocycloalkyl, 5 to 14-membered heterocycloalkyl, 5 to 12-membered heterocycloalkyl, etc. Heterocycloalkyl groups may include groups in which one hydrogen atom is removed from a non-aromatic heterocycle such as aziridine, azetidine, pyrrolidine, piperidine, N-methylpiperidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolinone, hydantoin, dioxolane, phthalimide, piperidine, pyrimidine-2,4(1H,3H)-dione, 1,4-dioxane, morpholine, thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S,S-oxide, piperazine, pyran, pyridone, 3-pyrroline, thiopyran, pyrone, tetrahydrofuran, tetrahydrothiophene, quinuclidine, tropane, isoxazolidine, benzo[d]isoxazolidine, oxazine, Azabicyclo[2,2,1]heptane, 2-azaspiro[3.3]heptane, 5-oxa-6-azaspiro[2.4]heptane, (1R,5S)-3-azabicyclo[3.2.1]octane, (1s,4s)-2-azabicyclo[2.2.2]octane, diazaspiro[5.5]undecane, diazabicyclo[2.2.1]heptane, 2-azaspiro[3.3]heptane, (1R,5S)-3-azabicyclo[3.2.1]octane, (1s,4s)-2-azabicyclo[2.2.2]octane, (1R,4R)-2-oxa-5-azabicyclo[2.2.2]octane, etc., but not limited thereto.

[0038] The term "heteroatom" refers to an atom other than carbon (C), and may be, for example, an O, N, P, Si or S atom, more specifically an N, O or S atom. The heterocycle, heteroaryl and heterocycloalkyl groups as described herein may include one or more heteroatoms, for example 1, 1 to 2, 1 to 3 or 1 to 4 heteroatoms.

[0039] The term "substitution" refers to replacing a hydrogen atom in a molecular structure with a substituent so that the valence of the designated atom is not exceeded and so that the substitution produces a chemically stable compound. For example, "group A is substituted with substituent B" or "group A has substituent B" means that the hydrogen atoms bound to the atoms (e.g., carbon) constituting the skeleton of group A are replaced by substituent B, so that group A and substituent B form a covalent bond. Therefore, it is essentially difficult or impossible for a group without removable hydrogen atoms to have a substituent. From this point of view, in the case of illustrating the range of combinations of various groups and substituents including groups with almost no substituents in this specification, it should be understood that the combination of groups and substituents that are obviously impossible to be substituted is excluded from the range. Non-limiting examples of such substituents may include those selected from halogens (F, Cl, Br or I), C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, hydroxyl, C 1-10 Alkoxy, amino, nitro, mercapto, thioether, imino, cyano, phosphino, carboxyl, carbamoyl, acetal, thiocarbonyl, sulfonyl, sulfonamide, keto, aldehyde, ester, acetyl, amide, oxo (=O), haloalkyl (e.g., trifluoromethyl), substituted aminoacyl and aminoalkyl, monocyclic or fused or non-fused polycyclic groups as carbocyclic cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), or monocyclic or fused or non-fused polycyclic groups as heterocycloalkyl (e.g., pyrrolidinyl, piperidinyl, piperazinyl) At least one of a cyclopentyl group, ...

[0040] The same or different types of one or more substituents mentioned above may be substituted at the same position or at different positions, and may be substituted continuously. The term "continuously" means that one substituent is substituted in the formula, and then another substituent is substituted continuously at the substituent, for example, in the case where an alkyl group is substituted, then a cycloalkyl group is substituted at the alkyl group, and a carbonyl group is substituted continuously at the cycloalkyl group, and the naming of carbonylcycloalkylalkyl may indicate that the group is formed by continuous substitution.

[0041] In the chemical structural formula shown in this specification, according to the typical way of expressing the chemical structural formula, the symbol (C) of the carbon atom and the symbol (H) of the hydrogen atom can be omitted, and it should be understood that, for example, even if the hydrogen atom symbol is not marked, the number of hydrogen atoms actually bonded to the carbon atom satisfies the valence of the carbon forming the skeleton. However, when deuterium (D) is shown in the chemical structural formula, it should be understood that deuterium (D) is bonded to carbon (C).

[0042] In the present specification, the symbol "-" used to connect atoms and / or groups may mean a single bond, and the symbol "=" may mean a double bond. The symbol may be omitted, and the symbol may be displayed when necessary (for example, in the case of specifying a bonding atom or a bonding position).

[0043] Unless otherwise specified, the binding direction of the linking groups described herein is arbitrary. The group L connected in the middle is -MW-, wherein -MW- can connect ring A and ring B in the same direction as the reading order from left to right to form It is also possible to connect ring A and ring B in the opposite direction of reading order from left to right to form

[0044] As used herein, the term "stereoisomer" refers to a compound having the same chemical formula or molecular formula but different in space. In this specification, stereoisomers include enantiomers and diastereomers, and diastereomers also include conformational isomers (such as rotational isomers) and cis / trans isomers, wherein each isomer and its mixture are included within the scope of the present invention. For example, since the stereochemical structure is not specified, formula (I) of the present invention may include stereoisomers of formula (I). Specifically, the solid line bond connected to the asymmetric carbon atom in the chemical structure formula Solid wedge bonds may be included to indicate the absolute arrangement of stereocenters and dotted wedge key It should be understood that stereoisomers of the example compounds described in this specification are also included in the scope of the present invention.

[0045] Heteroaryl derivatives

[0046] One aspect of the present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof:

[0047]

[0048] in:

[0049] Ring A is aromatic or non-aromatic C 6-12 A carbocyclic ring or a 5- to 12-membered heterocyclic ring, wherein Ring A has or does not have a ring selected from C 1-6 Alkyl, C1-6 Hydroxyalkyl, C 1-6 Haloalkyl, -CN, -NR A1 R A2 、-NO2、-OR A3 、-C(=O)-NR A1 R A2 、-C(=O)-OR A3 、-NH-C(=O)-(C 1-6 alkyl), =O, halogen and one or more substituents of 5- to 6-membered heteroaryl, wherein the heteroaryl is unsubstituted or substituted with C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy or halogen substitution;

[0050] R A1 To R A3 Each independently is H or C 1-6 alkyl;

[0051] X1 is C 1-6 Alkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Haloalkyl, C 1-6 Haloalkyl, C 3-12 Cycloalkyl or 3 to 12 membered heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are unsubstituted or replaced by C 1-6 Alkyl or C 1-6 haloalkyl substitution;

[0052] X2 is H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, -CN, -NR B1 R B2 、-NO2、-OR B3 or halogen;

[0053] R B1 To R B3 Each independently is H or C 1-6 alkyl;

[0054] Y1 is CR1 or N;

[0055] Y2 is CR2, C(-LZ) or N;

[0056] Y3 is CR3 or N;

[0057] R1 is H, C 1-6 Alkyl, C 1-6 Alkylamino or -CN;

[0058] R2 is H, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 1-6 Haloalkyl, -CN, -NH2 or halogen;

[0059] R3 is H, halogen, -OR4 or -NR5R6, or R3 and L are connected to form a 5- to 6-membered heterocyclic ring;

[0060] R4 is H, C 1-6 Alkyl, -(CH2)nO-(C 1-6 Alkyl), C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, -(CH2)n-(C 3-6 cycloalkyl), 3 to 6 membered heterocycloalkyl or -(CH2)n-(3 to 6 membered heterocycloalkyl), wherein the cycloalkyl and heterocycloalkyl have or do not have a member selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, -CN, -NR C1 R C2 、-NO2、-OR C3 and one or more substituents in halogen;

[0061] n is each independently an integer from 1 to 4;

[0062] R C1 To R C3 Each independently is H or C 1-6 alkyl;

[0063] R5 and R6 are each independently H or C 1-6 alkyl, or R5 and R6 are connected to each other to form a 3- to 12-membered heterocyclic ring, wherein the heterocyclic ring is unsubstituted or replaced by C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, -CN, -NR D1 R D2 、-NO2、-OR D3 , halogen or 3- to 6-membered heterocycloalkyl;

[0064] R D1 To R D3 Each independently is H or C 1-6 alkyl;

[0065] L is -NH-, Or L is connected to R3 to form a 5- to 6-membered heterocyclic ring, wherein ring B is a 3- to 8-membered heterocyclic ring containing a nitrogen atom in the ring, and ring B may or may not have a member selected from C 1-6 Alkyl, C1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 1-6 One or more substituents selected from haloalkyl, -OH and halogen;

[0066] Z is

[0067] Z1 is H, C 1-6 Alkyl, C 1-6 haloalkyl, -CN, halogen or 5- to 6-membered heteroaryl;

[0068] Z2 and Z3 are each independently H, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 1-6 Haloalkyl, halogen, C 3-12 Cycloalkyl, 3- to 12-membered heterocycloalkyl, -(CH2)m-(C 1-6 alkylamino), -(CH2)m-(C 3-12 -(CH2)m-(3 to 12-membered heterocycloalkyl) or -(CH2)m-NH-(3 to 12-membered heterocycloalkyl), wherein -CH2-, the cycloalkyl and heterocycloalkyl may or may not have a member selected from C 1-6 Alkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Haloalkyl, -OH, =O, -C(=O)-(C 1-6 alkoxy) and one or more substituents of 3 to 6-membered heterocycloalkyl;

[0069] m is each independently an integer from 1 to 4; and

[0070] The heterocyclic ring, heteroaryl group and heterocycloalkyl group each independently contain at least one heteroatom selected from N, S and O.

[0071] In one embodiment of the above formula (I),

[0072] Ring A is aromatic C 6-12 A carbocyclic or aromatic or non-aromatic 5- to 12-membered heterocyclic ring, wherein Ring A has or does not have a ring selected from C 1-6 Alkyl, -NR A1 R A2 、-OR A3 、-C(=O)-NR A1 R A2 、-C(=O)-OR A3 、-NH-C(=O)-(C 1-6 alkyl), =O, halogen and one or more substituents of 5- to 6-membered heteroaryl, wherein the heteroaryl is unsubstituted or substituted with C 1-6Alkyl, C 1-6 Alkoxy or halogen substitution;

[0073] R A1 To R A3 Each independently is H or C 1-6 alkyl;

[0074] The heterocyclic ring and the heteroaryl group each independently contain at least one heteroatom selected from N, S and O; and

[0075] X1, X2, Y1, Y2, Y3, L and Z are the same as defined above.

[0076] In another embodiment of the above formula (I),

[0077] Ring A is

[0078] A1 to A9 are each independently CH or N;

[0079] B1 to B3 are each independently CH2, NH, O or S;

[0080] wherein ring A has or does not have a member selected from C 1-6 Alkyl, -NR A1 R A2 、-OR A3 、-C(=O)-NR A1 R A2 、-C(=O)-OR A3 、-NH-C(=O)-(C 1-6 alkyl), =O, halogen and one or more substituents of 5- to 6-membered heteroaryl, wherein the heteroaryl is unsubstituted or substituted with C 1-6 Alkyl, C 1-6 Alkoxy or halogen substitution;

[0081] R A1 To R A3 Each independently is H or C 1-6 alkyl;

[0082] The heteroaryl group contains at least one heteroatom selected from N, S and O; and

[0083] X1, X2, Y1, Y2, Y3, L and Z are the same as defined above.

[0084] In another embodiment of the above formula (I),

[0085] X1 is C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-12Cycloalkyl or 3 to 12 membered heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are unsubstituted or replaced by C 1-6 Alkyl or C 1-6 haloalkyl substitution;

[0086] X2 is H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, -NR B1 R B2 or halogen;

[0087] R B1 and R B2 Each independently is C 1-6 alkyl;

[0088] The heterocycloalkyl groups each independently contain at least one heteroatom selected from N, S and O; and

[0089] Ring A, Y1, Y2, Y3, L and Z are the same as defined above.

[0090] In another embodiment of the above formula (I),

[0091] Ring A is aromatic C 6-12 A carbocyclic or aromatic or non-aromatic 5- to 12-membered heterocyclic ring, wherein Ring A has or does not have a ring selected from C 1-6 Alkyl, -NR A1 R A2 、-OR A3 、-C(=O)-NR A1 R A2 、-C(=O)-OR A3 、-NH-C(=O)-(C 1-6 alkyl), =O, halogen and one or more substituents of 5- to 6-membered heteroaryl, wherein the heteroaryl is unsubstituted or substituted with C 1-6 Alkyl, C 1-6 Alkoxy or halogen substitution;

[0092] R A1 To R A3 Each independently is H or C 1-6 alkyl;

[0093] X1 is C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-12 Cycloalkyl or 3 to 12 membered heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are unsubstituted or replaced by C 1-6 Alkyl or C 1-6 haloalkyl substitution;

[0094] X2 is H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, -NR B1 R B2 or halogen;

[0095] R B1 and R B2 Each independently is C 1-6 alkyl;

[0096] The heterocyclic ring, heteroaryl and heterocycloalkyl groups each independently contain at least one heteroatom selected from N, S and O; and

[0097] Y1, Y2, Y3, L and Z are the same as defined above.

[0098] In another embodiment of the above formula (I),

[0099] Y1 is CR1 or N;

[0100] Y2 is CR2, C(-LZ) or N;

[0101] Y3 is CR3 or N;

[0102] R1 is H or -CN;

[0103] R2 is H or halogen;

[0104] R3 is H, halogen, -OR4 or -NR5R6, or R3 and L are connected to form a 5- to 6-membered heterocyclic ring;

[0105] R4 is C 1-6 Alkyl, -(CH2)nO-(C 1-6 Alkyl), C 1-6 haloalkyl, 3 to 6 membered heterocycloalkyl or -(CH2)n-(3 to 6 membered heterocycloalkyl), wherein the cycloalkyl and heterocycloalkyl have or do not have a member selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, -CN, -NR C1 R C2 、-NO2、-OR C3 and one or more substituents of halogen;

[0106] n is each independently an integer from 1 to 4;

[0107] R C1 To R C3 Each independently is H or C 1-6 alkyl;

[0108] R5 and R6 are each independently H or C1-6 alkyl, or R5 and R6 are connected to each other to form a 3- to 12-membered heterocyclic ring, wherein the heterocyclic ring is a 4- to 6-membered monocyclic ring or a 5- to 12-membered spirocyclic ring, and the heterocyclic ring is unsubstituted or substituted with halogen or a 3- to 6-membered heterocycloalkyl;

[0109] The heterocyclic ring and heterocycloalkyl each independently contain at least one heteroatom selected from N, S and O; and

[0110] Ring A, X1, X2, L and Z are the same as defined above.

[0111] In another embodiment of the above formula (I),

[0112] L is -NH-, Or L is connected to R3 to form a 5- to 6-membered heterocyclic ring, wherein ring B is a 3- to 8-membered heterocyclic ring containing a nitrogen atom in the ring, and ring B may or may not have a member selected from C 1-6 Alkyl, C 1-6 one or more substituents of haloalkyl and halogen;

[0113] Z is

[0114] Z1 is H, -CN, halogen or 5- to 6-membered heteroaryl;

[0115] Z2 and Z3 are each independently H, C 1-6 Alkyl, C 1-6 Alkylamino, halogen, C 3-12 Cycloalkyl, 3- to 12-membered heterocycloalkyl, -(CH2)m-(C 1-6 alkylamino), -(CH2)m-(C 3-12 -(CH2)m-(3 to 12-membered heterocycloalkyl) or -(CH2)m-NH-(3 to 12-membered heterocycloalkyl), wherein -CH2-, the cycloalkyl and heterocycloalkyl may or may not have a member selected from C 1-6 Alkyl, deuterated C 1-6 Alkyl, -OH, =O, -C(=O)-(C 1-6 alkoxy) and one or more substituents of 3 to 6-membered heterocycloalkyl;

[0116] m is each independently an integer from 1 to 4;

[0117] The heterocyclic ring, heteroaryl and heterocycloalkyl groups each independently contain at least one heteroatom selected from N, S and O; and

[0118] Ring A, X1, X2, Y1, Y2 and Y3 are the same as defined above.

[0119] In another embodiment of the above formula (I),

[0120] Ring A is

[0121] A1 to A9 are each independently CH or N;

[0122] B1 to B3 are each independently CH2, NH, O or S;

[0123] wherein ring A has or does not have a member selected from C 1-6 Alkyl, -NR A1 R A2 、-OR A3 、-C(=O)-NR A1 R A2 、-C(=O)-OR A3 、-NH-C(=O)-(C 1-6 alkyl), =O, halogen and one or more substituents of 5- to 6-membered heteroaryl, wherein the heteroaryl is unsubstituted or substituted with C 1-6 Alkyl, C 1-6 Alkoxy or halogen substitution;

[0124] X1 is C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-12 Cycloalkyl or 3 to 12 membered heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are unsubstituted or replaced by C 1-6 Alkyl or C 1-6 haloalkyl substitution;

[0125] X2 is H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, -NR B1 R B2 or halogen;

[0126] R B1 and R B2 Each independently is C 1-6 alkyl;

[0127] Y1 is CR1 or N;

[0128] Y2 is CR2, C(-LZ) or N;

[0129] Y3 is CR3 or N;

[0130] R1 is H or -CN;

[0131] R2 is H or halogen;

[0132] R3 is H, halogen, -OR4 or -NR5R6, or R3 and L are connected to form a 5- to 6-membered heterocyclic ring;

[0133] R4 is C 1-6 Alkyl, -(CH2)nO-(C 1-6 Alkyl), C 1-6 haloalkyl, 3 to 6 membered heterocycloalkyl or -(CH2)n-(3 to 6 membered heterocycloalkyl), wherein the cycloalkyl and heterocycloalkyl have or do not have a member selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, -CN, -NR C1 R C2 、-NO2、-OR C3 and one or more substituents of halogen;

[0134] n is each independently an integer from 1 to 4;

[0135] R C1 To R C3 Each independently is H or C 1-6 alkyl;

[0136] R5 and R6 are each independently H or C 1-6 alkyl, or R5 and R6 are connected to each other to form a 3- to 12-membered heterocyclic ring, wherein the heterocyclic ring is a 4- to 6-membered monocyclic ring or a 5- to 12-membered spirocyclic ring, and the heterocyclic ring is unsubstituted or substituted with halogen or a 3- to 6-membered heterocycloalkyl;

[0137] L is -NH-, Or L is connected to R3 to form a 5- to 6-membered heterocyclic ring, wherein ring B is a 3- to 8-membered heterocyclic ring containing a nitrogen atom in the ring, and ring B may or may not have a member selected from C 1-6 Alkyl, C 1-6 one or more substituents of haloalkyl and halogen;

[0138] Z is

[0139] Z1 is H, -CN, halogen or 5- to 6-membered heteroaryl;

[0140] Z2 and Z3 are each independently H, C 1-6 Alkyl, C 1-6 Alkylamino, halogen, C 3-12 Cycloalkyl, 3- to 12-membered heterocycloalkyl, -(CH2)m-(C 1-6 alkylamino), -(CH2)m-(C 3-12-(CH2)m-(3 to 12-membered heterocycloalkyl) or -(CH2)m-NH-(3 to 12-membered heterocycloalkyl), wherein -CH2-, the cycloalkyl and heterocycloalkyl may or may not have a member selected from C 1-6 Alkyl, deuterated C 1-6 Alkyl, -OH, =O, -C(=O)-(C 1-6 alkoxy) and one or more substituents of 3 to 6-membered heterocycloalkyl;

[0141] m is each independently an integer from 1 to 4; and

[0142] The heterocyclic ring, heteroaryl group and heterocycloalkyl group each independently contain at least one heteroatom selected from N, S and O.

[0143] In another embodiment of the above formula (I),

[0144] L is -NH-,

[0145] The heterocyclic ring containing N may or may not be selected from C 1-6 Alkyl, C 1-6 one or more substituents of haloalkyl and halogen, or

[0146] L is connected to R3 to form a 5- to 6-membered heterocyclic ring containing N;

[0147] In addition to N, the heterocyclic ring containing N may or may not contain at least one heteroatom selected from S and O; and

[0148] Ring A, X1, X2, Y1, Y2, Y3 and Z are the same as defined above.

[0149] In a specific example, the scope of the present invention includes a compound selected from the following group or a pharmaceutically acceptable salt or stereoisomer thereof.

[0150] 1>1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one;

[0151] 2> 1-(4-((4-((5-chloro-4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one;

[0152] 3> 1-(4-((4-((5-chloro-2-methoxy-4-(pyridin-2-yloxy)phenyl)amino)-7-methoxyquinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one;

[0153] 4> 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-methyl-2-((1-methylazetidin-3-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one;

[0154] 5> 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one;

[0155] 6> 1-(4-((4-((5-chloro-4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-3-fluoropiperidin-1-yl)prop-2-en-1-one;

[0156] 7> 1-(4-((4-((4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one;

[0157] 8> 1-(4-((4-((5-chloro-4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one;

[0158] 9> 1-(4-((4-((4-((1-(5-fluoro-6-methylpyridin-3-yl)-1H-pyrazol-3-yl)oxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one;

[0159] 10> 1-(4-((7-methoxy-4-((2-methoxy-4-((1-(2-methoxypyrimidin-5-yl)-1H-pyrazol-3-yl)oxy)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one;

[0160] 11>1-(4-((4-((5-chloro-2-methoxy-4-(3-methoxyphenoxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one;

[0161] 12> 4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinoline-3-carbonitrile;

[0162] 13> methyl 4-(4-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-5-methoxy-2-methylphenoxy)benzoate;

[0163] 14> 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)-2-chloro-2-fluoroethan-1-one;

[0164] 15> 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-5-yl)oxy)-3,3-difluoropiperidin-1-yl)prop-2-en-1-one;

[0165] 16> 1-(3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-5-yl)oxy)-4,4-difluoropiperidin-1-yl)prop-2-en-1-one;

[0166] 17> 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one;

[0167] 18> 1-(5-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-yl)prop-2-en-1-one;

[0168] 19> 1-(3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one;

[0169] 20>1-(3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pyrrolidin-1-yl)prop-2-en-1-one;

[0170] 21>1-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)prop-2-en-1-one;

[0171] 22> N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(4-morpholinopiperidin-1-yl)quinazolin-6-yl)acrylamide;

[0172] 23> N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-morpholinequinazolin-6-yl)acrylamide;

[0173] 24> N-(4-((5-chloro-2-methoxy-4-(pyridin-2-yloxy)phenyl)amino)-7-methoxyquinazolin-6-yl)acrylamide;

[0174] 25> (E)-N-(4-((5-chloro-4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)but-2-enamide;

[0175] 26> (E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-5-chloroquinazolin-6-yl)-4-(dimethylamino)but-2-enamide;

[0176] 27> 1-(4-(8-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-yl)prop-2-en-1-one;

[0177] 28> N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)but-2-ynamide;

[0178] 29>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0179] 30>(R,E)-N-(4-((5-chloro-4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0180] 31>(R,E)-N-(4-((5-chloro-4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(pyrrolidin-2-yl)acrylamide;

[0181] 32>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0182] 33>(R,E)-N-(4-((5-chloro-2-methoxy-4-(pyridin-2-yloxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0183] 34>(R,E)-N-(8-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0184] 35> (E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(2-methyl-2-azabicyclo[3.1.0]hexan-3-yl)acrylamide;

[0185] 36>(E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpiperidin-2-yl)acrylamide;

[0186] 37>(S,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0187] 38> (E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino)but-2-enamide;

[0188] 39> (E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-4-(5-hydroxyhexahydrocyclopenta[c]pyrrol-2(1H)-yl)but-2-enamide;

[0189] 40>(E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)but-2-enamide;

[0190] 41>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0191] 42>(R,E)-N-(4-((5-chloro-4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0192] 43>(Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0193] 44>(S,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0194] 45>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methyl-5-oxopyrrolidin-2-yl)acrylamide;

[0195] 46>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0196] 47>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0197] 48>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0198] 49>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0199] 50>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0200] 51>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0201] 52>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-ethylpyrrolidin-2-yl)-2-fluoroacrylamide;

[0202] 53>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-(trifluoromethyl)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0203] 54>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-(trifluoromethyl)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0204] 55>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((1-methyl-1H-benzo[d]imidazol-6-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0205] 56>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0206] 57> (R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0207] 58>(R,Z)-N-(4-((5-chloro-2-methoxy-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0208] 59>(R,E)-N-(4-((5-chloro-2-methoxy-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0209] 60>(R,E)-2-Fluoro-N-(4-((5-fluoro-2-methoxy-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0210] 61>(R,Z)-2-Fluoro-N-(4-((5-fluoro-2-methoxy-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0211] 62>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(quinoxalin-6-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0212] 63>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(quinoxalin-6-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0213] 64>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(naphthalen-2-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0214] 65>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(naphthalen-2-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0215] 66>(R,E)-N-(4-((4-(Benzo[d]oxazol-6-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0216] 67> (R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((2-methylbenzo[d]oxazol-5-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0217] 68>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((2-methylbenzo[d]oxazol-5-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0218] 69>(E)-2-Fluoro-N-(4-((4-((2-hydroxy-2,3-dihydrobenzo[d]oxazol-5-yl)oxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-((R)-1-methylpyrrolidin-2-yl)acrylamide;

[0219] 70>(Z)-2-Fluoro-N-(4-((4-((2-hydroxy-2,3-dihydrobenzo[d]oxazol-5-yl)oxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-((R)-1-methylpyrrolidin-2-yl)acrylamide;

[0220] 71>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((1-methyl-2-oxo-1,2-dihydropyridin-4-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0221] 72>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0222] 73>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0223] 74>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-phenoxyphenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0224] 75>(R,E)-2-fluoro-N-(4-((4-(imidazo[1,2-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0225] 76>(R,Z)-2-fluoro-N-(4-((4-(imidazo[1,2-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0226] 77>(R,E)-2-fluoro-N-(4-((4-(imidazo[1,2-c]pyrimidin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0227] 78>(R,E)-N-(8-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0228] 79>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(pyrazolo[1,5-a]pyrimidin-6-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0229] 80>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(pyrazolo[1,5-a]pyrimidin-6-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0230] 81>(R,E)-N-(4-((4-(Benzo[d]thiazol-6-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0231] 82>(R,Z)-N-(4-((4-(Benzo[d]thiazol-6-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0232] 83>(R,Z)-N-(4-((4-(Benzo[d]thiazol-5-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0233] 84>(R,E)-N-(4-((4-(Benzo[d]thiazol-5-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0234] 85>(R,E)-N-(4-((4-(Benzo[d][1,3]dioxol-5-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0235] 86>(R,Z)-N-(4-((4-(Benzo[d][1,3]dioxol-5-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0236] 87>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(quinolin-7-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0237] 88>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(quinolin-7-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0238] 89>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((1-methyl-1H-indazol-6-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0239] 90>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((1-methyl-1H-indazol-6-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0240] 91>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0241] 92>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0242] 93>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0243] 94>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(2-methoxyethoxy)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0244] 95>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(2-methoxyethoxy)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0245] 96>(E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-3-((R)-1-methylpyrrolidin-2-yl)acrylamide;

[0246] 97>(Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-3-((R)-1-methylpyrrolidin-2-yl)acrylamide;

[0247] 98>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(difluoromethoxy)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0248] 99>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(difluoromethoxy)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0249] 100>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(2-morpholinethoxy)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0250] 101>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(2-morpholinethoxy)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0251] 102>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-fluoroquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0252] 103>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-fluoroquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0253] 104>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-ethoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0254] 105>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-methyl-2-(trifluoromethoxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0255] 106>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-cyclopropyloxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0256] 107>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-cyclopropyloxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0257] 108>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-methyl-2-(oxetan-3-yloxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0258] 109>(R,E)-tert-butyl 2-(3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(oxetan-3-yloxy)phenyl)amino)-7-methoxyquinazolin-6-yl)amino)-2-fluoro-3-oxoprop-1-en-1-yl)pyrrolidine-1-carboxylate;

[0259] 110>(E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-((3R)-hexahydro-1H-pyrrolizin-3-yl)acrylamide;

[0260] 111>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0261] 112>(S,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0262] 113>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(4,4-difluoropiperidin-1-yl)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0263] 114>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(3,3-difluoroazetidin-1-yl)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0264] 115>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(4-morpholinopiperidin-1-yl)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0265] 116>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(2-oxa-6-azaspiro[3.3]heptane-6-yl)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0266] 117> N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(2-oxa-6-azaspiro[3.3]heptane-6-yl)quinazolin-6-yl)acrylamide;

[0267] 118>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(methylamino)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0268] 119>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-6-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0269] 120>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0270] 121>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-3-(pyrrolidin-2-yl)acrylamide;

[0271] 122>(S,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0272] 123>(R,E)-N-(4-((4-(4-(dimethylamino)phenoxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0273] 124>(R,E)-methyl 4-(4-((6-(2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamido)-7-methoxyquinazolin-4-yl)amino)-5-methoxy-2-methylphenoxy)benzoate;

[0274] 125>(R,Z)-4-(4-((6-(2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide)-7-methoxyquinazolin-4-yl)amino)-5-methoxy-2-methylphenoxy)-N,N-dimethylbenzamide;

[0275] 126>(R,E)-4-(4-((6-(2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamido)-7-methoxyquinazolin-4-yl)amino)-5-methoxy-2-methylphenoxy)-N,N-dimethylbenzamide;

[0276] 127>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-(dimethylamino)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0277] 128>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0278] 129>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyphenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0279] 130>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyphenyl)amino)-7-morpholinoquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0280] 131>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpiperidin-2-yl)acrylamide;

[0281] 132>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0282] 133>(R,Z)-N-(4-((4-(3-acetamidophenoxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0283] 134>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(pyrrolidin-2-yl)acrylamide;

[0284] 135>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(pyrrolidin-2-yl)acrylamide;

[0285] 136>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-chloro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0286] 137>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-cyclopropyl-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0287] 138>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-cyclopropyl-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0288] 139>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0289] 140>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0290] 141>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-5-chloroquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0291] 142>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-5-chloroquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0292] 143>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((5-methyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0293] 144>(Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-cyano-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enamide;

[0294] 145>(E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enamide;

[0295] 146>(E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4,4-dimethylpent-2-enamide;

[0296] 147> N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-(1H-pyrazol-1-yl)acrylamide;

[0297] 148>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0298] 149>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0299] 150>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0300] 151>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-(methoxy-d3)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0301] 152>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-(methoxy-d3)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide;

[0302] 153>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-(methyl-d3)pyrrolidin-2-yl)acrylamide;

[0303] 154>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-(methyl-d3)pyrrolidin-2-yl)acrylamide;

[0304] 155>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-(methyl-d3)pyrrolidin-2-yl)acrylamide;

[0305] 156>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-(methyl-d3)pyrrolidin-2-yl)acrylamide; and

[0306] 157>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-(methyl-d3)pyrrolidin-2-yl)acrylamide.

[0307] The compound of formula (I) of the present invention may exist in the form of a pharmaceutically acceptable salt. Therefore, the scope of the compound of the present invention includes pharmaceutically acceptable salts of the compound represented by the above formula (I). As used herein, the term "pharmaceutically acceptable salt" refers to any organic acid or inorganic acid addition salt of a compound, which has a concentration that exhibits an effective effect and is relatively nontoxic and harmless to the patient, and wherein the side effects caused by the salt do not reduce the beneficial effects of the compound represented by formula (I).

[0308] In particular, pharmaceutically acceptable salts may be acid addition salts formed from free acids. Here, acid addition salts may be obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid and phosphorous acid, non-toxic organic acids such as aliphatic mono- and dicarboxylates, phenyl-substituted alkanoates, hydroxyalkanoates, alkanedioates, aromatic acids and aliphatic and aromatic sulfonic acids, and organic acids such as trifluoroacetic acid, acetic acid, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid and fumaric acid.

[0309] Types of such pharmaceutically acceptable salts can include sulfate, sulfite, nitrate, phosphate, pyrophosphate, chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, octanoate, acrylate, formate, isobutyrate, decanoate, heptanoate, propiolic acid, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, benzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, glycolate, malate, tartrate, mandelate, and the like.

[0310] Acid addition salts can be prepared by conventional methods, for example, by dissolving the derivative of formula (I) in an organic solvent (e.g., methanol, ethanol, acetone, dichloromethane or acetonitrile), followed by filtering and drying the precipitate produced by adding an organic acid or an inorganic acid, or by distilling the solvent and excess acid under reduced pressure, followed by drying and crystallization from an organic solvent.

[0311] In addition, pharmaceutically acceptable salts can be salts or metal salts obtained using alkali. As examples of metal salts, alkali metal or alkaline earth metal salts can be obtained by dissolving the compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and then evaporating and drying the filtrate. As alkali metal salts, sodium salts, potassium salts or calcium salts can be pharmaceutically suitable. In addition, the corresponding salt can be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (e.g., silver nitrate).

[0312] In addition, the compounds of the present invention may have a chiral carbon center and may therefore exist in the form of R or S isomers or mixtures, individual enantiomers or mixtures, or individual diastereomers or mixtures, all of which stereoisomers and mixtures thereof (e.g., racemic mixtures) are within the scope of the present invention.

[0313] In addition, the compounds of the present invention may include hydrates and solvates of the compounds of formula (I). Hydrates and solvates may be prepared using known methods and are preferably non-toxic and water-soluble. In particular, hydrates and solvates may preferably be those obtained by combining 1 to 5 molecules of water and alcohol solvents (particularly ethanol, etc.) with the compounds, respectively.

[0314] In addition, the compounds of the present invention may form metabolites in vivo after administration, and specifically, such metabolites may be produced by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, enzymatic cleavage, etc. of the administered compounds. For example, compounds produced by a method comprising contacting a compound of the present invention with a mammal for a period of time sufficient to produce a metabolite of the compound of the present invention may also fall within the scope of the present invention.

[0315] In addition, the compound of the present invention itself has little or no pharmacological activity, but when applied to the body, it can be prepared in the form of a prodrug, which can be converted into a compound with the desired activity by, for example, hydrolysis. Such a prodrug can be a derivative of a compound containing a bioreactive functional group, and the bioreactive functional group can be cut off from the compound under biological conditions (in vivo or in vitro) or otherwise reacted to provide the compound. Generally, the prodrug is inactive or at least has a lower activity than the compound, which makes the compound show its activity after being cut off from the bioreactive functional group. The bioreactive functional group can be hydrolyzed or oxidized under biological conditions to form a compound. For example, a prodrug can contain a biohydrolyzable group. Examples of biohydrolyzable groups include, but are not limited to, biohydrolyzable phosphates, biohydrolyzable esters, biohydrolyzable amides, biohydrolyzable carbonates, biohydrolyzable carbamates, and biohydrolyzable ureides.

[0316] Uses of heteroaryl derivatives

[0317] Another aspect of the present invention provides a pharmaceutical use of a compound represented by formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof.

[0318] The compound of formula (I) according to the present invention or its pharmaceutically acceptable salt or stereoisomer can inhibit the activity of human epidermal growth factor receptor 2 (HER2). Specifically, the compound of formula (I) according to the present invention or its pharmaceutically acceptable salt or stereoisomer can inhibit the binding between HER2 and ligand.

[0319] Therefore, the present invention provides a HER2 inhibitor comprising a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof as an active ingredient.

[0320] In addition, the present invention provides a method for inhibiting HER2 activity, which comprises treating a sample or a cell with a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof.

[0321] Therefore, the compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof can be used to treat or prevent HER2-related diseases, especially cancer.

[0322] In particular, the compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof exhibits excellent inhibitory activity against HER2 mutations (e.g., HER2 T798I, HER2 L755S, HER2 T862A, etc.), and can be used to treat or prevent cancer types induced by HER2 or HER2 mutations.

[0323] Here, "prevention" refers to any action that inhibits or delays the occurrence, spread and recurrence of a disease, and "treatment" refers to any action that improves or beneficially changes the symptoms of a disease by administering a compound.

[0324] Therefore, the present invention provides use of a compound represented by formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof for treating or preventing HER2-related diseases.

[0325] The present invention also provides use of a compound represented by formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof in the preparation of a drug for treating or preventing HER2-related diseases.

[0326] The present invention also provides a method for treating or preventing HER2-related diseases, which comprises administering a therapeutically effective amount of a compound represented by formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof to a subject in need thereof.

[0327] Specifically, the present invention provides a method for treating or preventing a disease selected from pseudomyxoma, intrahepatic bile duct cancer, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphocytic leukemia, basal cell carcinoma, ovarian epithelial cancer, ovarian germ cell cancer, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colorectal cancer, chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampulla of Vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, nasal cancer, non-small cell lung cancer, tongue cancer, astrocytoma, small cell lung cancer, childhood brain cancer, childhood lymphoma, childhood leukemia, small intestinal cancer, meningioma, esophageal cancer, glioma, renal pelvis cancer, kidney cancer, heart cancer, duodenal cancer, malignant tumors, A method for treating at least one of soft tissue tumors, malignant bone cancer, malignant lymphoma, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureteral cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, gastric cancer, gastric carcinoid, gastrointestinal stromal cancer, Wilms' tumor, breast cancer, sarcoma, penile cancer, pharyngeal cancer, gestational choriocarcinoma, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, rectal cancer, rectal carcinoid, vaginal cancer, spinal cord cancer, vestibular schwannoma, pancreatic cancer, salivary gland cancer, Kaposi's sarcoma, Paget's disease, tonsil cancer, squamous cell carcinoma, lung adenocarcinoma, lung cancer, lung squamous cell carcinoma, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleural cancer, blood cancer and thymic cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof.

[0328] Here, the term "subject in need" refers to any animal, especially mammals, such as monkeys, cows, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, rats, rabbits and guinea pigs, including humans (patients) suffering from or likely to suffer from a disease; specifically, it may refer to mammals including humans. In addition, a subject in need may refer to a biological sample.

[0329] In addition, "administering" means providing a predetermined substance to a subject in need thereof by any appropriate method, and the administration of the compound of the present invention can be achieved by any common route (such as oral or parenteral route) as long as the route allows the substance to reach the target tissue.

[0330] The present invention also provides a pharmaceutical composition comprising the compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof as an active ingredient.

[0331] The present invention also provides a pharmaceutical composition for treating or preventing HER2-related diseases, wherein the composition contains a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof as an active ingredient.

[0332] HER2-related diseases can be, for example, cancer. Cancer includes all cancers for which the pharmaceutical composition of the present invention can show therapeutic and preventive efficacy due to inhibition of HER2 activity, and can be solid cancer or blood cancer. In addition, cancer includes not only primary cancer, but also metastatic cancer. As a specific example, the HER2-related disease can be selected from pseudomyxoma, intrahepatic bile duct cancer, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphocytic leukemia, basal cell carcinoma, ovarian epithelial cancer, ovarian germ cell cancer, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colorectal cancer, chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampulla of Vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, nasal cancer, non-small cell lung cancer, tongue cancer, astrocytoma, small cell lung cancer, childhood brain cancer, childhood lymphoma, childhood leukemia, small intestine cancer, meningioma, esophageal cancer, At least one of glioma, renal pelvic cancer, kidney cancer, heart cancer, duodenal cancer, malignant soft tissue tumor, malignant bone cancer, malignant lymphoma, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureteral cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, gastric cancer, gastric carcinoid, gastrointestinal stromal cancer, Wilms' tumor, breast cancer, sarcoma, penile cancer, pharyngeal cancer, gestational choriocarcinoma, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, rectal cancer, rectal carcinoid, vaginal cancer, spinal cord cancer, vestibular schwannoma, pancreatic cancer, salivary gland cancer, Kaposi's sarcoma, Paget's disease, tonsil cancer, squamous cell carcinoma, lung adenocarcinoma, lung cancer, lung squamous cell carcinoma, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleural cancer, blood cancer and thymic cancer, but not limited thereto.

[0333] The pharmaceutical composition may include conventional and nontoxic pharmaceutically acceptable additives, which are mixed into the preparation according to conventional methods. Therefore, the invention provides a pharmaceutical composition, which contains a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof as an active ingredient, and contains a pharmaceutically acceptable additive. For example, the pharmaceutical composition may further contain a pharmaceutically acceptable carrier, diluent or excipient. In one embodiment, the invention provides a pharmaceutical composition, which contains a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier. As a pharmaceutically acceptable carrier, at least one of saline solution, sterile water, Ringer's solution, buffered saline solution, glucose solution, maltodextrin solution, glycerol, ethanol, etc. can be used, and if necessary, other conventional additives such as antioxidants, buffer solutions and antibacterial agents can be added.

[0334] In addition, the pharmaceutical composition can be formulated into an injection preparation such as an aqueous solution, a suspension or emulsion, a pill, a capsule, a granule or a tablet by additionally adding a diluent, a dispersant, a surfactant, a binder and a lubricant. Therefore, the composition of the present invention can be a patch, a liquid, a pill, a capsule, a granule, a tablet, a suppository, etc.

[0335] These preparations can be prepared by conventional methods for formulation in the art or by methods disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA), and can be formulated into various preparations according to diseases or ingredients.

[0336] Furthermore, in addition to the compound represented by formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, the pharmaceutical composition of the present invention may further contain one or more active ingredients exhibiting the same or similar medical effects.

[0337] The pharmaceutical composition can be prepared into various preparation forms for oral administration (eg, tablets, pills, powders, capsules, syrups or emulsions) or parenteral administration (eg, intramuscular, intravenous or subcutaneous injections).

[0338] For example, pharmaceutical compositions can be made into preparations for oral administration, wherein the additives used can include cellulose, calcium silicate, corn starch, lactose, sucrose, glucose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talcum, surfactants, suspending agents, emulsifiers, diluents, etc. Specifically, solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. Such solid preparations can be prepared by mixing at least one excipient (such as starch, calcium carbonate, sucrose, lactose, gelatin, etc.) into the composition. In addition to simple excipients, lubricants such as magnesium stearate and talcum can also be made. In addition, as liquid preparations for oral administration, suspensions, emulsions, syrups, etc. can be exemplified, and in addition to water and liquid paraffin commonly used as simple diluents, liquid preparations can also contain various excipients, such as wetting agents, sweeteners, spices and preservatives.

[0339] In addition, examples of preparations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. For non-aqueous solutions and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used. As a suppository base, Witepsol TM , polyethylene glycol, Tween TM 61. Cocoa butter, laurel oil, glycerin gelatin, etc. The injection may contain conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers and preservatives.

[0340] The compounds or compositions of the present invention may be administered to a patient in a therapeutically effective amount or a pharmaceutically effective amount.

[0341] As used herein, the term "therapeutically effective amount" refers to the amount of a compound represented by formula (I) that can effectively treat or prevent HER2-related diseases. Specifically, "therapeutically effective amount" refers to an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to any medical treatment, and the effective dosage level of a compound or composition can be determined based on factors including individual type, age and sex, severity, disease type, drug activity, sensitivity to the drug, administration time, route of administration, excretion rate, duration of treatment, drugs used in combination with the composition, and other factors well known in the medical field.

[0342] The compound or composition of the present invention can be used as a single therapeutic agent or in combination with other therapeutic agents, can be used sequentially or simultaneously with a therapeutic agent on the market, and can be used in a single dose or multiple doses. Taking all of the above factors into consideration, it is important that the amount to be used is the minimum amount and the maximum effect can be obtained without side effects, and such an amount can be easily determined by those skilled in the art.

[0343] The dosage of the pharmaceutical composition of the present invention can be determined by experts according to various factors such as the patient's condition, age, sex and complications. The active ingredients of the pharmaceutical composition of the present invention have excellent safety and can therefore be used in an amount equal to or greater than the determined dosage.

[0344] Furthermore, in order to prepare a medicament using the compound represented by formula (I), an adjuvant, a diluent, a carrier and the like may be mixed, and the compound may be prepared as a combined preparation together with other active agents so as to exhibit a synergistic effect of the active ingredients.

[0345] The matters mentioned in the uses, compositions and methods of treatment of the present invention apply in the same manner unless they contradict each other. DETAILED DESCRIPTION

[0346] Hereinafter, the present invention will be described in detail by examples and experimental examples. However, the following examples and experimental examples are only illustrative of the present invention, and the scope of the present invention is not limited thereto.

[0347] Analysis and purification conditions

[0348] 1. HPLC analysis conditions

[0349] Instrument name: e2695 from Waters

[0350] Column: YMC-Pack ODS-AM, 150 x 4.6 mm, 3 μm, 12 nm, 40 °C

[0351] Mobile phase: 10% → 90% acetonitrile / H2O + 0.1% TFA

[0352] Analysis time: 20 minutes, flow rate: 1 mL / min

[0353] UV detector: 254nm

[0354] 2. LC-MS analysis conditions

[0355] Instrument name: AQUITY UPLC from Waters

[0356] Column: AQUITY BEH C18, 50x 2.1mm, 5μm, 40℃

[0357] Mobile phase: acetonitrile / H2O+0.1% TFA

[0358] Flow rate: 0.6mL / min

[0359] UV detector: 254nm

[0360] 3.MPLC purification conditions

[0361] Instrument name: from Teledyne ISCO Ltd. Rf+

[0362] UV detector: 254nm

[0363] 4. Prep-HPLC purification conditions (A)

[0364] Instrument name: from Teledyne ISCO Ltd. HP125

[0365] column: Prep Shield RP18, 250x 19mm, 10μm

[0366] Mobile phase: acetonitrile / 0.1% TFA H2O

[0367] Flow rate: 25mL / min

[0368] UV detector: 254nm

[0369] 5. Prep-HPLC purification conditions (B)

[0370] Instrument name: from Teledyne ISCO Ltd. ACCQPrep HP125

[0371] column: Prep Shield RP18, 250x 19mm, 10μm

[0372] Mobile phase: acetonitrile / 0.1% FA H2O

[0373] Flow rate: 25mL / min

[0374] UV detector: 254nm

[0375] 6. 1 H NMR

[0376] Instrument name: Bruker Ascend TM 400(400MHz)

[0377] Commercially available reagents are used without further purification. In this specification, room temperature (rt) or ambient temperature refers to a temperature of 5°C to 40°C, 10°C to 30°C as an example, and 20°C to 27°C as another example, and is not strictly limited to the above range. A rotary evaporator is used for reduced pressure concentration or solvent distillation removal.

[0378] Preparation Example 1: Preparation of 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one (Example 1)

[0379] [Reaction Scheme 1]

[0380]

[0381] [Step 1] Preparation of 7-(5-methoxy-2-methyl-4-nitrophenoxy)-[1,2,4]triazolo[1,5-a]pyridine

[0382] 1-Fluoro-5-methoxy-2-methyl-4-nitrobenzene (1.0 equiv.), [1,2,4]triazolo[1,5-a]pyridin-7-ol (1.2 equiv.), and Cs2CO3 (2.4 equiv.) were dissolved in DMSO (0.2 M), and then stirred at 80°C for 2 hours. A solid was formed by pouring ice water into the reaction mixture, which was then filtered to obtain the desired compound as a yellow solid (yield: 99%, MS (ESI): m / z 301 [M+H] + ).

[0383] [Step 2] Preparation of 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylaniline 7-(5-methoxy-2-methyl-4-nitrophenoxy)-[1,2,4]triazolo[1,5-a]pyridine (1.0 equivalent) prepared in step 1, ammonium chloride (0.45 equivalent) and iron (4.5 equivalent) were dissolved in ethanol-water solution (3:1), and then stirred at 80°C for 1 hour. The mixture was filtered through a celite filter and then concentrated. The reaction mixture was purified using MPLC (dichloromethane:methanol) to obtain the desired compound as a brown solid (yield: 98%, MS (ESI): m / z 271 [M+H] + ).

[0384] [Step 3] Preparation of N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylbenzene 7-methoxy-6-nitroquinazolin-4-amine

[0385] 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylaniline (1.0 equivalent) obtained in step 2 and 4-chloro-7-methoxy-6-nitroquinazoline (1.0 equivalent) were dissolved in sec-butyl alcohol (0.05 M), and then 4M HCl (0.2 equivalent) dissolved in 1,4-dioxane was added thereto, followed by stirring at 100° C. for 1 hour. Diethyl ether was added to the reaction mixture, and then the desired compound was obtained as a yellow solid through a filter (yield: 95%, MS (ESI): m / z 474 [M+H] + ).

[0386] [Step 4] Preparation of N 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methyl Phenyl)-7-methoxyquinazoline-4,6-diamine

[0387] N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-methoxy-6-nitroquinazolin-4-amine (1.0 equivalent) obtained in step 3 and SnCl2.2H2O (5.0 equivalent) were dissolved in ethyl acetate (0.1 M), and the mixture was stirred at 60°C for 2 hours. Aqueous ammonia solution was added to the reaction mixture, which was then concentrated. The reaction mixture was purified using MPLC (dichloromethane:methanol) to obtain the desired compound as a pale yellow solid (yield: 65%, MS (ESI): m / z 444 [M+H] + ).

[0388] [Step 5] Preparation of 4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5- tert-Butyl (methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)piperidine-1-carboxylate

[0389] The N prepared in step 4 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-methoxyquinazoline-4,6-diamine (1.0 equiv.) and tert-butyl 4-oxopiperidine-1-carboxylate (3.0 equiv.) were dissolved in acetic acid (0.1 M), followed by stirring at room temperature for 1 hour. Sodium triacetoxyborohydride (4.0 equiv.) was added to the mixture, followed by stirring at room temperature for 1 hour. The organic matter was extracted with saturated aqueous NaHCO3 and dichloromethane, and then the residual water in the collected organic layer was removed with MgSO4, and the collected organic layer was concentrated. The desired compound obtained as a yellow solid was used for the subsequent reaction without further purification (yield: 100%, MS (ESI): m / z 627 [M+H] + ).

[0390] [Step 6] Preparation of N 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methyl Phenyl)-7-methoxy-N 6 -(Piperidin-4-yl)quinazoline-4,6-diamine

[0391] The compound tert-butyl 4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)piperidine-1-carboxylate (1.0 equivalent) obtained in step 5 was dissolved in dichloromethane (0.1M), and trifluoroacetic acid (TFA, 60.0 equivalent) was then added thereto, followed by stirring at room temperature for 1 hour, and then concentrated. The reaction mixture was purified using MPLC (dichloromethane:methanol) to obtain the desired compound as a yellow solid (yield: 59%, MS (ESI): m / z 527 [M+H] + ).

[0392] [Step 7] Preparation of 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy- 5-Methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one

[0393] The N obtained in step 6 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-methoxy-N 6 -(Piperidin-4-yl)quinazoline-4,6-diamine (1.0 equivalent) was dissolved in tetrahydrofuran (THF, 0.1 M), 1 M NaHCO3 aqueous solution (5.0 equivalent) was added thereto at 0°C, acryloyl chloride (1.0 equivalent) was added thereto, and then stirred at 0°C for 30 minutes. The reaction mixture was concentrated and then purified by prep-HPLC to obtain the desired compound as a milky white solid (yield: 34%, MS (ESI): m / z 581 [M+H] + ).

[0394] Preparation of compounds of Examples 2 to 4

[0395] The compounds of Examples 2 to 4 according to the invention were prepared in a similar manner to that of Preparation Example 1.

[0396] Chemical structural formulas, compound names, 1 H NMR, MS, yields, HPLC data and purity are summarized in Table 1 below.

[0397] [Table 1]

[0398]

[0399]

[0400] Preparation Example 2: Preparation of 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one (Example 5)

[0401] [Reaction Scheme 2]

[0402]

[0403] [Step A1] Preparation of 7-(2-chloro-5-methoxy-4-nitrophenoxy)-[1,2,4]triazolo[1,5-a]pyridine1-Chloro-2-fluoro-4-methoxy-5-nitrobenzene (1.0 equivalent), [1,2,4]triazolo[1,5-a]pyridin-7-ol (1.0 equivalent) were dissolved in DMF (0.1 M), Cs2CO3 (1.2 equivalent) was added thereto, and then stirred at 120°C for 1 hour. The reaction mixture was put into ice water and stirred to form a solid, the obtained solid was filtered with a filter, and the obtained desired compound as a yellow solid was used for the subsequent reaction without further purification (yield: 100%, MS (ESI): m / z 321 [M+H] + ).

[0404] [Step A2] Preparation of 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyaniline 7-(2-chloro-5-methoxy-4-nitrophenoxy)-[1,2,4]triazolo[1,5-a]pyridine (1.0 equivalent) obtained in step A1 and iron (4.5 equivalent) were dissolved in an ethanol-water solution (3:1, 0.566 M), ammonium chloride (0.45 equivalent) was added thereto, and then stirred at 80°C for 1 hour. The reaction mixture was filtered through a filter, and the organic matter was extracted with water and dichloromethane, and then the remaining water in the collected organic layer was removed with MgSO4, and the collected organic layer was concentrated. The reaction mixture was purified using MPLC (dichloromethane: methanol) to obtain the desired compound as a yellow solid (yield: 36%, MS (ESI): m / z 291 [M+H] + ).

[0405] [Reaction Scheme 3]

[0406]

[0407] [Step B1] Preparation of 4-chloro-7-methoxyquinazolin-6-ol

[0408] After dissolving 4-chloro-7-methoxyquinazolin-6-yl acetate (1.0 equivalent) in methanol (0.7 M), aqueous ammonia (20.0 equivalent) was added, and the reaction mixture was stirred at room temperature for 2 hours. After adding ether to the reaction mixture to form a solid, the resulting solid was filtered to obtain the desired compound as a yellow solid (yield: 100%, MS (ESI): m / z 211 [M+H] + ).

[0409] [Step B2] Preparation of tert-butyl 4-((4-chloro-7-methoxyquinazolin-6-yl)oxy)piperidine-1-carboxylate

[0410] 4-Chloro-7-methoxyquinazolin-6-ol (1.0 equivalent) obtained in step B1, tert-butyl 4-hydroxypiperidine-1-carboxylate (1.4 equivalent) and triphenylphosphine (1.3 equivalent) were dissolved in dichloromethane, and then di-tert-butyl azodicarboxylate (DTBAD; 1.5 equivalent) was slowly added thereto at 0°C and stirred at room temperature for 2 hours. The reaction mixture was concentrated and purified using MPLC (dichloromethane: methanol) to obtain the desired compound as a white solid (yield: 52%, MS (ESI): m / z 394 [M+H] + ).

[0411] [Step B3] Preparation of 4-chloro-7-methoxy-6-(piperidin-4-yloxy)quinazoline

[0412] To tert-butyl 4-((4-chloro-7-methoxyquinazolin-6-yl)oxy)piperidine-1-carboxylate (1.0 equiv.) obtained in step B2 was added 4.0 M HCl (20.0 equiv.) dissolved in 1,4-dioxane, followed by stirring at room temperature for 4 hours. Diethyl ether was added to the reaction mixture to form a solid, which was then filtered to obtain the desired compound as a pale yellow solid (yield: 100%, MS (ESI): m / z 294 [M+H] + ).

[0413] [Step B4] Preparation of 1-(4-((4-chloro-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-ene-1- ketone

[0414] After dissolving 4-chloro-7-methoxy-6-(piperidin-4-yloxy)quinazoline (1.0 equivalent) obtained in step B3 in dichloromethane (0.2M), triethylamine (3.5 equivalents) and acryloyl chloride (1.05 equivalents) were added thereto at 0°C and stirred for 1 hour. Organic matter was extracted by adding an aqueous NaHCO3 solution and dichloromethane to the reaction mixture, and the residual water in the collected organic layer was removed with MgSO4, and the collected organic layer was concentrated. The concentrated reaction mixture was purified using MPLC to obtain the desired compound as a white solid (yield: 100%, MS (ESI): m / z 348 [M+H] + ).

[0415] [Step B5] Preparation of 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2- (methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one

[0416] 1-(4-((4-chloro-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one (1.0 equivalent) obtained in Step B4 and 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyaniline (1.0 equivalent) obtained in Step A2 of Reaction Scheme 2 were dissolved in sec-butyl alcohol (0.1 M), and then 4.0 M HCl (0.3 equivalent) dissolved in 1,4-dioxane was added thereto, and stirred at 110° C. for 1 hour. The reaction mixture was concentrated and then purified using prep-HPLC to obtain the desired compound as a brown oil (yield: 10%, MS (ESI): m / z 603 [M+H] + ).

[0417] Preparation of compounds of Examples 6 to 14

[0418] The compounds of Examples 6 to 14 according to the invention were prepared in a similar manner to that of Preparation Example 2.

[0419] Chemical structural formulas, compound names, 1 H NMR, MS, yields, HPLC data and purity are summarized in Table 2 below.

[0420] [Table 2]

[0421]

[0422]

[0423]

[0424] Preparation Example 3: Preparation of 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-5-yl)oxy)-3,3-difluoropiperidin-1-yl)prop-2-en-1-one (Example 15)

[0425] [Reaction Scheme 4]

[0426]

[0427] [Step 1] Preparation of N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylbenzene 4-Methyl-5-fluoro-7-methoxyquinazolin-4-amine

[0428] (E)-N'-(2-cyano-3-fluoro-5-methoxyphenyl)-N,N-dimethylformamidine (1.0 equivalent) and 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylaniline (1.5 equivalent) obtained in step 2 of Preparation Example 1 were dissolved in acetic acid (52.0 equivalent), and then stirred at 50°C for 16 hours. After the reaction, the organic matter was extracted with a saturated NaHCO3 aqueous solution and ethyl acetate, the organic layer was washed with brine, and the residual water was removed with Na2SO4, followed by filtration and concentration. The reaction mixture was purified by MPLC (dichloromethane:methanol) to obtain the desired compound as a yellow solid (yield: 72%, MS (ESI): m / z 447 [M+H] + ).

[0429] [Step 2] Preparation of 4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5- tert-Butyl (methylphenyl)amino)-7-methoxyquinazolin-5-yl)oxy)-3,3-difluoropiperidine-1-carboxylate

[0430] N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-5-fluoro-7-methoxyquinazolin-4-amine (1.0 equivalent) obtained in step 1, tert-butyl 3,3-difluoro-4-hydroxypiperidine-1-carboxylate (2.0 equivalent) and KOtBu (3.0 equivalent) were dissolved in THF:DMF=1:1 (0.02M) and stirred at 100°C for 16 hours under nitrogen. The reaction mixture was concentrated and purified by MPLC (dichloromethane:methanol) to obtain the desired compound as a yellow solid (yield: 51%, MS (ESI): m / z 664 [M+H] + ).

[0431] [Step 3] Preparation of N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylbenzene 4-(3,3-difluoropiperidin-4-yl)oxy)-7-methoxyquinazolin-4-amine

[0432] Tert-butyl 4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-5-yl)oxy)-3,3-difluoropiperidine-1-carboxylate (1.0 equiv.) obtained in step 2 and TFA (10.0 equiv.) were dissolved in dichloromethane (0.1 M) and stirred at room temperature for 1 hour. The reaction mixture was concentrated and purified by MPLC (dichloromethane:methanol) to obtain the desired compound as an orange solid (yield: 84%, MS (ESI): m / z 564 [M+H] + ).

[0433] [Step 4] Preparation of 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy- 5-Methylphenyl)amino)-7-methoxyquinazolin-5-yl)oxy)-3,3-difluoropiperidin-1-yl)prop-2-en-1-one

[0434] N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-5-((3,3-difluoropiperidin-4-yl)oxy)-7-methoxyquinazolin-4-amine (1.0 equivalent) obtained in step 3 and 1M NaHCO3 aqueous solution (5.0 equivalent) were dissolved in tetrahydrofuran (0.1M), and then acryloyl chloride (1.0 equivalent) was added thereto at 0°C. The mixture was stirred at room temperature for 30 minutes, and the reaction mixture was concentrated and purified by prep-HPLC to obtain the desired compound as a pale yellow solid (yield: 34%, MS (ESI): m / z 618 [M+H] + ).

[0435] Preparation of compounds of Examples 16 to 17

[0436] The compounds of Examples 16 to 17 according to the invention were prepared in a similar manner to that of Example 3.

[0437] Chemical structural formulas, compound names, 1 H NMR, MS, yields, HPLC data and purity are summarized in Table 3 below.

[0438] [Table 3]

[0439]

[0440]

[0441] Preparation Example 4: Preparation of 1-(5-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-yl)prop-2-en-1-one (Example 18)

[0442] [Reaction Scheme 5]

[0443]

[0444] [Step 1] Preparation of 4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methyl (phenyl)amino)-7-methoxyquinazolin-6-ol

[0445] 4-Chloro-7-methoxyquinazolin-6-ol (1.0 equivalent), 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylaniline (1.0 equivalent) obtained in Step 2 of Preparation Example 1, and 4M HCl (0.2 equivalent) dissolved in 1,4-dioxane were dissolved in sec-butanol (0.1 M), and then stirred at 80° C. for 2 hours. The reaction mixture was concentrated and purified by MPLC (dichloromethane:methanol) to obtain the desired compound as a white solid (yield: 75%, MS (ESI): m / z 445 [M+H] + ).

[0446] [Step 2] Preparation of 5-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5- tert-butyl (methylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate

[0447] 4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-ol (1.0 equivalent) obtained in step 1, tert-butyl 5-(p-toluenesulfonyloxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate (1.2 equivalent) and K2CO3 (2.0 equivalent) were dissolved in DMF (0.1M) and stirred at 110°C for 16 hours. After the reaction, the organic matter was extracted with distilled water and ethyl acetate, the organic layer was washed with brine, and then the residual water was removed with Na2SO4, followed by filtration and concentration. The reaction mixture was purified by MPLC (dichloromethane:methanol) to obtain the desired compound as a yellow solid (yield: 79%, MS (ESI): m / z 640 [M+H] + ).

[0448] [Step 3] Preparation of 6-((2-azabicyclo[2.2.1]heptane-5-yl)oxy)-N-(4-([1,2,4]triazolo [1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-methoxyquinazolin-4-amine

[0449] 5-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester (1.0 equivalent) obtained in step 2 and TFA (20.0 equivalent) were dissolved in DCM (0.5M), and then stirred at room temperature for 1 hour. The reaction mixture was concentrated and then purified by MPLC (dichloromethane:methanol) to obtain the desired compound as a yellow solid (yield: 89%, MS (ESI): m / z 540[M+H] + ).

[0450] [Step 4] Preparation of 1-(5-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy- 5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-yl)propan-2- En-1-one

[0451] 6-((2-azabicyclo[2.2.1]heptane-5-yl)oxy)-N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-methoxyquinazolin-4-amine (1.0 equivalent) obtained in step 3 and 1M NaHCO3 aqueous solution (5.0 equivalent) were dissolved in tetrahydrofuran (0.1M), and then acryloyl chloride (1.0 equivalent) was added thereto at 0°C. The mixture was stirred at room temperature for 30 minutes, and then the reaction mixture was concentrated and purified by prep-HPLC to obtain the desired compound as a white solid (yield: 22%, MS (ESI): m / z 594 [M+H] + ).

[0452] Preparation of compounds of Examples 19 to 20

[0453] The compounds of Examples 19 to 20 according to the invention were prepared in a similar manner to that of Example 4.

[0454] Chemical structural formulas, compound names, 1 H NMR, MS, yields, HPLC data and purity are summarized in Table 4 below.

[0455] [Table 4]

[0456]

[0457]

[0458] Preparation Example 5: Preparation of 1-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)prop-2-en-1-one (Example 21)

[0459] [Reaction Scheme 6]

[0460]

[0461] [Step 1] Preparation of 7-(2-hydroxyethoxy)-6-nitroquinazolin-4(3H)-one

[0462] Ethylene glycol (1.0 equivalent) was dissolved in anhydrous tetrahydrofuran (1.5 M), and NaH (0.7 equivalent) was slowly added to the solution at 0°C. After the addition was completed, the temperature was raised to room temperature and then stirred for 1 hour. Then, 7-fluoro-6-nitroquinazolin-4 (3H) -one (0.3 equivalent) was added to the reaction mixture and stirred at 75°C for 16 hours. After acetic acid was slowly added to the reaction mixture at 0°C to adjust the pH to 7, the organic matter was extracted with water and chloroform: isopropanol = 4: 1 (v / v), and then after removing the residual water in the collected organic layer with Na2SO4, the collected organic layer was filtered and concentrated under reduced pressure. The concentrated reaction mixture was purified using MPLC (dichloromethane: methanol) to obtain the desired compound as a light yellow solid (yield: 12%, MS (ESI): m / z252 [M + H] + ).

[0463] [Step 2] Preparation of 4-chloro-7-(2-chloroethoxy)-6-nitroquinazoline

[0464] 7-(2-Hydroxyethoxy)-6-nitroquinazolin-4(3H)-one (1.0 equivalent) obtained in step 1 and SOCl2 (0.1 M) were added thereto, DMF (0.1 equivalent) was added thereto, and the mixture was stirred at 110°C for 1 hour. The reaction mixture was concentrated under reduced pressure to obtain the desired compound as a white solid (which was used for the subsequent reaction without further purification) (yield: 100%, MS (ESI): m / z 287 [M+H] + ).

[0465] [Step 3] Preparation of N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylbenzene 2-(2-chloroethoxy)-7-(2-chloroethoxy)-6-nitroquinazolin-4-amine

[0466] 4-Chloro-7-(2-chloroethoxy)-6-nitroquinazoline (1.0 equivalent) obtained in step 2 was dissolved in isopropanol (0.1 M), and then 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylaniline (1.1 equivalent) prepared in step 2 of preparation example 1 was added thereto, followed by stirring at 60° C. for 1 hour. The reaction mixture was cooled and filtered to obtain a solid, which was washed with isopropanol. The obtained solid was vacuum dried to obtain the desired compound as a yellow solid (yield: 65%, MS (ESI): m / z 522 [M+H] + ).

[0467] [Step 4] Preparation of N 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methyl Phenyl)-7-(2-chloroethoxy)quinazoline-4,6-diamine

[0468] N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-(2-chloroethoxy)-6-nitroquinazolin-4-amine (1.0 equivalent) obtained in step 3 was dissolved in ethyl acetate (0.05M), and SnCl2.2H2O (5.0 equivalent) was then added thereto, followed by stirring at 60°C for 2 hours. The reaction mixture was cooled to 0°C, and aqueous ammonia was then slowly added thereto. Organic matter was extracted by adding a saturated NaHCO3 aqueous solution and ethyl acetate to the reaction mixture, and then after removing residual water in the collected organic layer with Na2SO4, the collected organic layer was filtered and concentrated under reduced pressure. The reaction mixture was purified by MPLC (dichloromethane:methanol) to obtain the desired compound as a white solid (yield: 83%, MS (ESI): m / z 492 [M+H] + ).

[0469] [Step 5] Preparation of N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylbenzene 7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-4-amine

[0470] The N obtained in step 4 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-(2-chloroethoxy)quinazoline-4,6-diamine (1.0 equiv) was dissolved in DMF (0.1 M), and then K2CO3 (1.02 equiv) and KI (1.0 equiv) were added thereto, and the mixture was stirred at 130°C for 16 hours. Ethyl acetate and brine were added to the reaction mixture to extract organic matter, and then after removing residual water in the collected organic layer with Na2SO4, the collected organic layer was filtered and concentrated under reduced pressure. The concentrated reaction mixture was purified using MPLC (dichloromethane:methanol) to obtain the desired compound as a yellow solid (yield: 60%, MS (ESI): m / z 456 [M+H] + ).

[0471] [Step 6] Preparation of 1-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methyl (phenyl)amino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)prop-2-en-1-one

[0472] N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-4-amine (1.0 equivalent) obtained in step 5 was dissolved in dichloromethane (0.05M), and then acrylic acid (3.5 equivalents), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 3.5 equivalents) and N,N-diisopropylethylamine (DIPEA, 2.5 equivalents) were added thereto, followed by stirring at room temperature for 16 hours. The reaction mixture was concentrated and then purified using MPLC (dichloromethane:methanol) to obtain the desired compound as a yellow solid (yield: 5%, MS (ESI): m / z 510 [M+H] + ).

[0473] [Table 5]

[0474]

[0475] Preparation Example 6: Preparation of N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(4-morpholinopiperidin-1-yl)quinazolin-6-yl)acrylamide (Example 22)

[0476] [Reaction Scheme 7]

[0477]

[0478] [Step 1] Preparation of 4-chloro-7-fluoro-6-nitroquinazoline

[0479] 7-Fluoro-6-nitroquinazoline-4(3H)-one (1.0 eq.) and DMF (0.1 eq.) were dissolved in SOCl2 (20.0 eq.) and then stirred at 80°C for 4 hours. The reaction mixture was concentrated and dissolved in dichloromethane, to which ether was added. The resulting solid was filtered and then dried in vacuo to obtain a yellow solid. The obtained yellow solid was used for subsequent reactions without further purification (yield: 36%, MS (ESI): m / z 228 [M+H] + ).

[0480] [Step 2] Preparation of N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylbenzene 7-Fluoro-6-nitroquinazolin-4-amine

[0481] 4-Chloro-7-fluoro-6-nitroquinazoline (1.0 equivalent) obtained in step 1 and 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylaniline (1.0 equivalent) prepared in step 2 of preparation example 1 were dissolved in isopropanol (0.2M), and then stirred at 50°C for 30 minutes. The reaction mixture was filtered to obtain a solid, and the obtained solid was washed with diethyl ether to obtain the desired compound as a milky white solid (yield: 72%, MS (ESI): m / z 462 [M+H] + ).

[0482] [Step 3] Preparation of N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylbenzene 4-Morpholinopiperidin-1-yl)-7-(4-morpholinopiperidin-1-yl)-6-nitroquinazolin-4-amine

[0483] N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-fluoro-6-nitroquinazolin-4-amine (1.0 equivalent) obtained in step 2, 4-(piperidin-4-yl)morpholine (2.2 equivalents) and DIPEA (4.0 equivalents) were dissolved in 1,4-dioxane (0.3M), and then stirred at 110°C for 16 hours. The reaction mixture was concentrated and then purified by MPLC to obtain the desired compound as a yellow solid (yield: 79%, MS (ESI): m / z 612 [M+H] + ).

[0484] [Step 4] Preparation of N 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methyl phenyl)-7-(4-morpholinopiperidin-1-yl)quinazoline-4,6-diamine

[0485] N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-(4-morpholinopiperidin-1-yl)-6-nitroquinazolin-4-amine (1.0 equivalent) obtained in step 3 and SnCl2.2H2O (5.0 equivalent) were dissolved in ethyl acetate (0.1 M), and the mixture was stirred at 60°C for 16 hours. Aqueous ammonia solution was added to the reaction mixture, which was then concentrated. The reaction mixture was purified using MPLC to obtain the desired compound as a pale yellow solid (yield: 33%, MS (ESI): m / z 582 [M+H] + ).

[0486] [Step 5] Preparation of N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methyl (phenyl)amino)-7-(4-morpholinopiperidin-1-yl)quinazolin-6-yl)acrylamide

[0487] The N obtained in step 4 4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-(4-morpholinopiperidin-1-yl)quinazoline-4,6-diamine (1.0 equivalent) was dissolved in dichloromethane (0.1M), and then DIPEA (3.0 equivalent) was added thereto, followed by stirring at 0°C. Then, acryloyl chloride (1.05 equivalent) was added thereto, and stirred at 0°C for 1 hour. The reaction mixture was concentrated and purified using prep-HPLC to obtain the desired compound as a yellow solid (yield: 3%, MS (ESI): m / z 636[M+H] + ).

[0488] Preparation of compounds of Examples 23 to 25

[0489] The compounds of Examples 23 to 25 according to the invention were prepared in a similar manner to that of Example 6.

[0490] Chemical structural formulas, compound names, 1 H NMR, MS, yields, HPLC data and purity are summarized in Table 6 below.

[0491] [Table 6]

[0492]

[0493]

[0494] Preparation Example 7: (E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-5-chloroquinazolin-6-yl)-4-(dimethylamino)but-2-enamide (Example 26)

[0495] [Reaction Scheme 8]

[0496]

[0497] [Step 1] Preparation of 4-(1H-benzo[d][1,2,3]triazol-1-yl)-5-chloroquinazolin-6-amine

[0498] 6-Amino-5-chloroquinazolin-4-ol (1.0 equivalent) was dissolved in acetonitrile (0.1 M), and then benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP, 3.0 equivalent), 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU, 4.0 equivalent) were added thereto, followed by stirring at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure to obtain the desired compound as a brown oil, and the obtained desired compound was used for the subsequent reaction without further purification (yield: 15%, MS (ESI): m / z 297 [M+H]+ ).

[0499] [Step 2] Preparation of N 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methyl Phenyl)-5-chloroquinazoline-4,6-diamine

[0500] 4-(1H-benzo[d][1,2,3]triazol-1-yl)-5-chloroquinazolin-6-amine (1.0 equivalent) obtained in step 1 and 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylaniline (1.0 equivalent) obtained in step 2 of preparation example 1 were dissolved in isopropanol (0.1 M), refluxed at 90° C. for 10 minutes, and then p-TsOH (0.1 equivalent) was added to the reaction mixture, and refluxed at 90° C. for 30 minutes. Dichloromethane (0.05 M), brine, and saturated aqueous NaHCO3 solution were added to the reaction mixture to extract organic matter, and then after removing residual water with Na2SO4, the collected organic layer was filtered and concentrated under reduced pressure. The concentrated mixture was purified by MPLC (dichloromethane:methanol) and then purified using prep-HPLC. The compound obtained by prep-HPLC was collected and concentrated, and saline was added thereto, and stirred at room temperature for 1 hour. After the reaction, the obtained solid was filtered and then dried to obtain the desired compound as a yellow solid (yield: 15%, MS (ESI): m / z 448 [M+H] + ).

[0501] [Step 3] Preparation of (E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy- 5-( ...

[0502] The N obtained in step 2 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-5-chloroquinazoline-4,6-diamine (1.0 equivalent) was dissolved in acetonitrile (0.1 M), then cooled to 0°C, to which (E)-4-(dimethylamino)but-2-enoyl chloride (1.0 equivalent) was added, followed by stirring at 0°C for 1 hour. Dichloromethane (0.05 M) and a saturated aqueous NaHCO3 solution were added to the reaction mixture to extract organic matter, and after removing residual water in the collected organic layer with Na2SO4, the collected organic layer was filtered and concentrated under reduced pressure. The concentrated mixture was purified using prep-HPLC to obtain the desired compound as a pale yellow solid (yield: 26%, MS (ESI): m / z 559 [M+H] + ).

[0503] [Table 7]

[0504]

[0505] Preparation Example 8: Preparation of 1-(4-(8-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-yl)prop-2-en-1-one (Example 27)

[0506] [Reaction Scheme 9]

[0507]

[0508] [Step 1] Preparation of 8-chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine

[0509] 6-(Methylthio)pyrimido[5,4-d]pyrimidin-4-ol (1.0 equiv.) and DMF (1.6 equiv.) were dissolved in dichloromethane (0.5 M), and oxalyl chloride (2.0 equiv.) was then slowly added thereto at 0° C. The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated to obtain the desired compound as a white solid, which was then used in the subsequent reaction without further purification (yield: 100%, MS (ESI): m / z 213 [M+H] + ).

[0510] [Step 2] Preparation of N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylbenzene 6-(Methylthio)pyrimido[5,4-d]pyrimidin-4-amine

[0511] 8-Chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine (1.0 equivalent) obtained in step 1 and 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylaniline (1.0 equivalent) obtained in step 2 of preparation example 1 were dissolved in isopropanol (0.5 M), and then the reaction mixture was stirred at 45° C. for 4 hours. The reaction mixture was concentrated and purified using MPLC to obtain the desired compound as a yellow solid (yield: 16%, MS (ESI): m / z 447 [M+H] + ).

[0512] [Step 3] Preparation of N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylbenzene 6-(Methylsulfonyl)pyrimido[5,4-d]pyrimidin-4-amine

[0513] N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-6-(methylthio)pyrimido[5,4-d]pyrimidin-4-amine (1.0 equiv.) obtained in step 2 was dissolved in dichloromethane (0.06 M), and then meta-chloroperbenzoic acid (m-CPBA, 2.3 equiv.) was slowly added thereto at 0° C. The reaction mixture was stirred at room temperature for 2 hours. Saturated aqueous NaHCO3 solution was added to the reaction mixture, and the organic matter was extracted with DCM, and then after removing the residual water in the collected organic layer with MgSO4, the collected organic layer was filtered and concentrated under reduced pressure. The desired compound obtained as a white solid was used for the subsequent reaction without further purification (yield: 83%, MS (ESI): m / z 479[M+H] + ).

[0514] [Step 4] Preparation of 4-(8-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methyl tert-butyl (phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazine-1-carboxylate

[0515] N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-6-(methylsulfonyl)pyrimido[5,4-d]pyrimidin-4-amine (1.0 equiv.) obtained in step 3 was dissolved in 1,4-dioxane (0.1 M), and then tert-butyl piperazine-1-carboxylate (1.7 equiv.) and DIPEA (1.3 equiv.) were added thereto. The reaction mixture was stirred at 70° C. for 2 hours. Saturated aqueous NaHCO3 solution was added to the reaction mixture, the organic matter was extracted with DCM, and then after removing the residual water in the collected organic layer with MgSO4, the collected organic layer was filtered and concentrated under reduced pressure. The desired compound obtained as a brown liquid was used for the subsequent reaction without further purification (yield: 100%, MS (ESI): m / z 585 [M+H] + ).

[0516] [Step 5] Preparation of N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylbenzene 6-(piperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-amine

[0517] Tert-butyl 4-(8-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazine-1-carboxylate (1.0 equivalent) obtained in step 4 was dissolved in dichloromethane (0.06M), trifluoroacetic acid (40.0 equivalent) was added thereto, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated and then purified using MPLC to obtain the desired compound as an orange solid (yield: 82%, MS (ESI): m / z 485[M+H] + ).

[0518] [Step 6] Preparation of 1-(4-(8-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy- 5-Methylphenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-yl)prop-2-en-1-one

[0519] N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-6-(piperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-amine (1.0 equivalent) obtained in step 5 was dissolved in DCM (0.04M), triethylamine (8.0 equivalent) was added thereto, and then acryloyl chloride (1.5 equivalent) was added thereto at 0°C. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated and then purified using prep-HPLC to obtain the desired compound as a yellow solid (yield: 29%, MS (ESI): m / z 539[M+H] + ).

[0520] [Table 8]

[0521]

[0522] Preparation Example 9: Preparation of N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)but-2-ynamide (Example 28)

[0523] [Reaction Scheme 10]

[0524]

[0525] [Step 1] Preparation of N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methyl (phenyl)amino)-7-methoxyquinazolin-6-yl)but-2-ynamide

[0526] Butynoic acid (3.0 equivalents) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU, 3.0 equivalents) were dissolved in DMF (0.5 M) and stirred at 50° C. for 30 minutes. 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-methoxyquinazoline-4,6-diamine (1.0 equivalent) and DIPEA (3.0 equivalent) were added to the reaction mixture, followed by stirring at 50° C. for 1 hour. The reaction mixture was purified using prep-HPLC to obtain the desired compound (yield: 7%, MS (ESI): m / z 510 [M+H] + ).

[0527] [Table 9]

[0528]

[0529] Preparation Example 10: (R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide (Example 29)

[0530] [Reaction Scheme 11]

[0531]

[0532] [Step 1] Preparation of (2-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5- (methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-2-oxoethyl)phosphonic acid diethyl ester

[0533] 2-(Diethoxyphosphoryl)acetic acid (3.0 equivalents) and 1,1'-carbonyldiimidazole (CDI, 3.0 equivalents) were dissolved in tetrahydrofuran (0.5 M), followed by stirring at 40° C. for 30 minutes. 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-methoxyquinazoline-4,6-diamine (1.0 equivalent) was added to the mixture, followed by stirring at 40°C for 1 hour. Water was added, the organic matter was extracted with dichloromethane, and then after the remaining water in the collected organic layer was removed with MgSO4, the collected organic layer was concentrated. The obtained yellow desired compound was used for the subsequent reaction without further purification (yield: 100%, MS (ESI): m / z 622 [M+H] + ).

[0534] [Step 2] Preparation of (R,E)-2-(3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2- (methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-3-oxoprop-1-en-1-yl)pyrrolidine- 1-Carboxylic acid tert-butyl ester

[0535] The diethyl (2-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-2-oxoethyl)phosphonate (1.0 equivalent) obtained in step 1 was dissolved in tetrahydrofuran (0.05M), and then lithium bis(trimethylsilyl)amide (LiHMDS, 1.0 equivalent) was added thereto at -78°C. The mixture was stirred at -78°C for 1 hour, and then (R)-tert-butyl 2-formylpyrrolidine-1-carboxylate (3.3 equivalents) was added thereto and stirred at room temperature for 1 hour. Water was added, the organic matter was extracted with dichloromethane, and then after removing the remaining water in the collected organic layer with MgSO4, the collected organic layer was concentrated. The desired compound obtained as a yellow solid was used for the subsequent reaction without further purification (yield: 100%, MS (ESI): m / z 667 [M+H] + ).

[0536] [Step 3] Preparation of (R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy (5-(methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(pyrrolidin-2-yl)acrylamide

[0537] The compound (R,E)-tert-butyl 2-(3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-3-oxoprop-1-en-1-yl)pyrrolidine-1-carboxylate (1.0 equivalent) obtained in step 2 was dissolved in dichloromethane (0.1M), and then TFA (60.0 equivalent) was added thereto and stirred at room temperature for 1 hour. The reaction mixture was concentrated and purified by MPLC (dichloromethane:methanol) to obtain the desired compound as a yellow solid (yield: 59%, MS (ESI): m / z 567 [M+H] + ).

[0538] [Step 4] Preparation of (R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy (5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide

[0539] (R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(pyrrolidin-2-yl)acrylamide (1.0 equivalent) obtained in step 3 and 37% formaldehyde (5.0 equivalent) were dissolved in 1,2-dichloroethane (DCE, 0.1M), followed by stirring at room temperature for 1 hour. Sodium triacetoxyborohydride (4.0 equivalent) was added to the mixture, followed by stirring at 80°C for 1 hour. Saturated aqueous NaHCO3 solution and dichloromethane were added to extract organic matter, and then residual water in the collected organic layer was removed with MgSO4, and the collected organic layer was concentrated. The reaction mixture was purified by MPLC (dichloromethane:methanol) to obtain the desired compound as a white solid (yield: 33%, MS (ESI): m / z 581 [M+H] + ).

[0540] Preparation of compounds of Examples 30 to 37

[0541] In a similar manner to the preparation of Example 10, the compounds of Examples 30 to 37 according to the invention were prepared.

[0542] Chemical structural formulas, compound names, 1 H NMR, MS, yields, HPLC data and purity are summarized in Table 10 below.

[0543] [Table 10]

[0544]

[0545]

[0546]

[0547] Preparation Example 11: (E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino)but-2-enamide (Example 38)

[0548] [Reaction Scheme 12]

[0549]

[0550] [Step 1] Preparation of (E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy- (5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-4-bromobut-2-enamide

[0551] The N prepared in step 4 of Preparation Example 1 was 4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-methoxyquinazoline-4,6-diamine (1.0 equivalent) was dissolved in acetonitrile (0.2M), and then (E)-3-bromoacryloyl chloride (3.0 equivalent) and DIPEA (4.0 equivalent) were added thereto at 0°C. The reaction mixture was reacted at 0°C for 1 minute, and then water was added thereto, and the organic matter was extracted with ethyl acetate (EA). The remaining water in the collected organic layer was removed with Na2SO4, and the collected organic layer was concentrated. The desired compound obtained as a brown oil was used for the subsequent reaction without further purification (yield: 100%, MS (ESI): m / z 590 [M+H] + ).

[0552] [Step 2] Preparation of (E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy- 5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino) But-2-enamide

[0553] (E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-4-bromobut-2-enamide (1.0 equivalent) obtained in step 1, KI (1.8 equivalent) and K2CO3 (2.3 equivalent) were dissolved in DMF (0.2M), followed by reaction at 40°C for 1 hour. The reaction mixture was purified using prep-HPLC to obtain the desired compound as a white solid (yield: 8%, MS (ESI): m / z 659 [M+H] + ).

[0554] Preparation of compounds of Examples 39 to 40

[0555] The compounds of Examples 39 to 40 according to the invention were prepared in a similar manner to that of Example 11.

[0556] Chemical structural formulas, compound names, 1 H NMR, MS, yields, HPLC data and purity are summarized in Table 11 below.

[0557] [Table 11]

[0558]

[0559]

[0560] Preparation Example 12: (R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide (Example 41) and (R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide (Example 111)

[0561] [Reaction Scheme 13]

[0562]

[0563] [Step 1] Preparation of (2-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5- (methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-1-fluoro-2-oxoethyl)phosphonic acid diethyl ester

[0564] 2-(Diethoxyphosphoryl)-2-fluoroacetic acid (2.0 equivalents) and HATU (3.0 equivalents) were dissolved in DMF (0.5 M), followed by stirring at 50° C. for 30 minutes. 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-methoxyquinazoline-4,6-diamine (1.0 equivalent) and DIPEA (3.0 equivalent) were added to the mixture, followed by stirring at 50° C. for 1 hour. Ice water was poured into the reaction mixture to form a solid, which was then filtered to obtain the desired compound as a yellow solid (yield: 95%, MS (ESI): m / z 640 [M+H] + ).

[0565] [Step 2] Preparation of (R,E / Z)-2-(3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)- (2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-2-fluoro-3-oxoprop-1-en-1-yl) Pyrrolidine-1-carboxylic acid tert-butyl ester

[0566] Diethyl (2-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-1-fluoro-2-oxoethyl)phosphonate (1.0 equiv.) obtained in step 1 was dissolved in DMF (0.5 M), and then NaH (1.5 equiv.) was added at 0° C. The mixture was stirred at 0° C. for 30 minutes, and then (R)-tert-butyl 2-formylpyrrolidine-1-carboxylate (2.0 equiv.) was added thereto and stirred at room temperature for 1 hour. Ice water was poured into the reaction mixture to form a solid, which was then filtered to obtain the desired compound as a yellow solid (yield: 85%, MS (ESI): m / z 685[M+H]+ ).

[0567] [Step 3] Preparation of (R, E / Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methyl (5-(2-( ...

[0568] The (R,E / Z)-tert-butyl 2-(3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-2-fluoro-3-oxoprop-1-en-1-yl)pyrrolidine-1-carboxylate (1.0 equivalent) obtained in step 2 was dissolved in dichloromethane (0.1 M), and then TFA (60.0 equivalent) was added thereto, and the mixture was stirred at room temperature for 1 hour and then concentrated. The concentrated mixture was purified using MPLC (dichloromethane:methanol) to obtain the desired compound as a yellow solid (yield: 57%, MS (ESI): m / z 585 [M+H] + ).

[0569] [Step 4] Preparation of (R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy (5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide and (R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)- 7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide

[0570] (R,E / Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(pyrrolidin-2-yl)acrylamide (1.0 equiv.) obtained in step 3 and 37% formaldehyde (5.0 equiv.) were dissolved in DCE (0.1 M) and stirred at room temperature for 1 hour. Sodium triacetoxyborohydride (4.0 equiv.) was added to the mixture, followed by stirring at 80°C for 1 hour. Saturated aqueous NaHCO3 solution and dichloromethane were added to the reaction mixture to extract organic matter, residual water was removed with MgSO4, and the organic layer was concentrated. The reaction mixture was purified using MPLC (dichloromethane:methanol) to obtain the desired compound as a yellow solid.

[0571] ((R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide: Yield: 39%, MS (ESI): m / z 599 [M+H] +, ((R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide: Yield: 9%, MS (ESI): m / z 599 [M+H] + ).

[0572] Preparation of Compounds of Examples 42 to 110 and 112 to 143

[0573] In a similar manner to the preparation of Example 12, the compounds of Examples 42 to 110 and 112 to 143 according to the invention were prepared.

[0574] Chemical structural formulas, compound names, 1 H NMR, MS, yields, HPLC data and purity are summarized in Table 12 below.

[0575] [Table 12]

[0576]

[0577]

[0578]

[0579]

[0580]

[0581]

[0582]

[0583]

[0584]

[0585]

[0586]

[0587]

[0588]

[0589]

[0590]

[0591]

[0592]

[0593]

[0594]

[0595]

[0596]

[0597]

[0598]

[0599]

[0600]

[0601] Preparation Example 13: Preparation of (Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-cyano-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enamide (Example 144)

[0602] [Reaction Scheme 14]

[0603]

[0604] [Step A1] Preparation of 2-methyl-2-(4-(oxetan-3-yl)piperazin-1-yl)propanal

[0605] After 2-bromo-2-methylpropanal (2.0 equivalents) was dissolved in dichloromethane (0.15 M), 1-(oxetane-3-yl)piperazine (1.0 equivalents) was slowly added thereto at 0°C. DIPEA (1.0 equivalents) was added to the reaction mixture and stirred at room temperature for 16 hours. Organic matter was extracted by adding water and dichloromethane to the reaction mixture, and then the residual water in the collected organic layer was removed with Na2SO4, and the collected organic layer was concentrated to obtain the desired compound as a yellow liquid (yield: 100%, MS (ESI): m / z 213 [M+H] + ).

[0606] [Reaction Scheme 15]

[0607]

[0608] [Step B1] Preparation of N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5- (Methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-cyanoacetamide

[0609] Cyanoacetic acid (2.0 equivalents), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, 2.0 equivalents) and DIPEA (3.0 equivalents) were dissolved in DMF (0.1 M), and then N obtained in step 4 of Preparation Example 1 was added thereto. 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-methoxyquinazoline-4,6-diamine (1.0 equiv.) was stirred at room temperature for 2 hours. The solid produced by adding the reaction mixture to cold water was filtered and then dried in vacuo to obtain the desired compound as a yellow solid. The desired compound was used for the subsequent reaction without further purification (yield: 100%, MS (ESI): m / z 511 [M+H] + ).

[0610] [Step B2] Preparation of (Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy (5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-cyano-4-methyl-4-(4-(oxetan-3-yl) Piperazin-1-yl)pent-2-enamide

[0611] N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-cyanoacetamide (1.0 equivalent) obtained in step B1 and 2-methyl-2-(4-(oxetan-3-yl)piperazin-1-yl)propanal (2.0 equivalent) obtained in step A1 of reaction scheme 14 were dissolved in dichloromethane (0.1M), and then pyrrolidine (6.0 equivalent) and trimethylsilyl chloride (4.0 equivalent) were added thereto at 0°C, followed by stirring for 3 hours. Water and brine were added to the reaction mixture, the organic matter was extracted with dichloromethane, and then the residual water in the collected organic layer was removed with Na2SO4, and the collected organic layer was concentrated. The reaction mixture was purified by prep-HPLC to obtain the desired compound as a yellow solid (yield: 68%, MS (ESI): m / z 705 [M+H] + ).

[0612] Preparation of the compounds of Examples 145 and 146

[0613] In a similar manner to the preparation of Example 13, the compounds of Examples 145 and 146 according to the invention were prepared.

[0614] Chemical structural formulas, compound names, and 1 H NMR, MS, yields, HPLC data and purity are summarized in Table 13 below.

[0615] [Table 13]

[0616]

[0617] Preparation Example 14: Preparation of N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-(1H-pyrazol-1-yl)acrylamide (Example 147)

[0618] [Reaction Scheme 16]

[0619]

[0620] [Step 1] Preparation of 2-(1H-pyrazol-1-yl)acrylic acid

[0621] 2-Bromoacrylic acid (1.0 equiv.), 1H-pyrazole (1.5 equiv.), CuI (0.2 equiv.), Cs2CO3 (2.5 equiv.) and N 1 ,N 2 -bis(furan-2-ylmethyl)oxalamide (BFMO, 0.2 equivalent) was dissolved in DMSO (0.5M) and then stirred at 80°C for 1 hour. Water and brine were added to the reaction mixture, the organic matter was extracted with ethyl acetate, and then the residual water in the collected organic layer was removed with Na2SO4, and the collected organic layer was concentrated. The reaction mixture was purified by MPLC (dichloromethane:methanol) to obtain the desired compound as a yellow solid (yield: 6%, MS (ESI): m / z 139 [M+H] + ).

[0622] [Step 2] Preparation of N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methyl (phenyl)amino)-7-methoxyquinazolin-6-yl)-2-(1H-pyrazol-1-yl)acrylamide

[0623] After dissolving 2-(1H-pyrazol-1-yl)acrylic acid (2.0 equivalents) and propylphosphonic acid (5.0 equivalents) prepared in Step 1 of Preparation Example 14 in DMF (0.01 M), DIPEA (1.0 equivalents) and N-(2-(1H-pyrazol-1-yl)acrylic acid (2.0 equivalents) obtained in Step 4 of Preparation Example 1 were added thereto. 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)-7-methoxyquinazoline-4,6-diamine (1.0 equivalent). The mixture was stirred at room temperature for 2 hours. The reaction mixture was added to cold water, and the resulting solid was filtered and then purified by prep-HPLC to obtain the desired compound as a yellow solid (yield: 4%, MS (ESI): m / z 564 [M+H] + ).

[0624] [Table 14]

[0625]

[0626] Preparation Example 15: Preparation of (R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide (Example 149) and (R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide (Example 150)

[0627] [Reaction Scheme 17]

[0628]

[0629] [Step 1] Preparation of 5-fluoro-4-methyl-2-nitrophenol

[0630] 3-Fluoro-4-methylphenol (1.0 equivalent) was dissolved in dichloromethane (0.4M), and then 70% nitric acid (1.5 equivalent) was added at 0°C and stirred for 30 minutes at 0°C. After water was added to the reaction mixture and the organic matter was extracted with dichloromethane, the remaining water in the collected organic layer was removed with Na2SO4, and the collected organic layer was concentrated. The reaction mixture was purified by MPLC (hexane: ethyl acetate) to obtain the desired compound as a yellow solid (yield: 63%).

[0631] [Step 2] Preparation of 1-fluoro-5-(methoxy-d3)-2-methyl-4-nitrobenzene

[0632] The 5-fluoro-4-methyl-2-nitrophenol (1.0 equivalent) prepared in step 1 was dissolved in DMF (0.5M), and then iodomethane-d3 (3.0 equivalents) and K2CO3 (3.0 equivalents) were added thereto, and the mixture was stirred at room temperature for 8 hours. Saturated NaHCO3 aqueous solution was added to the reaction mixture, and organic matter was extracted with ethyl acetate. Then, Na2SO4 was used to remove the residual water in the collected organic layer, and the collected organic layer was concentrated. The reaction mixture was purified by MPLC (hexane: ethyl acetate) to obtain the desired compound as a yellow solid (yield: 80%).

[0633] [Step 3] Preparation of 7-(5-(methoxy-d3)-2-methyl-4-nitrophenoxy)-[1,2,4]triazolo[1,5- a]pyridine

[0634] 1-Fluoro-5-(methoxy-d3)-2-methyl-4-nitrobenzene (1.0 equiv.) prepared in step 2 was dissolved in DMSO (0.25 M), and then [1,2,4]triazolo[1,5-a]pyridin-7-ol (1.2 equiv.) and Cs2CO3 (2.4 equiv.) were added thereto, and the mixture was stirred at 80°C for 1 hour. Ice water was added to the reaction mixture to form a solid, and the resulting solid was filtered through a filter to obtain the desired compound as a brown solid. The desired compound obtained was used for the subsequent reaction without further purification (yield: 100%, MS (ESI): m / z 304 [M+H] + ).

[0635] [Step 4] Preparation of 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methyl aniline

[0636] 7-(5-(methoxy-d3)-2-methyl-4-nitrophenoxy)-[1,2,4]triazolo[1,5-a]pyridine (1.0 equiv.), ammonium chloride (0.45 equiv.) and iron (4.5 equiv.) prepared in step 3 were dissolved in an ethanol-water solution (3:1), and then stirred at 80°C for 1 hour. The mixture was filtered through a celite filter and then concentrated to obtain the desired compound as a brown solid. The desired compound obtained was used for the subsequent reaction without further purification (yield: 92%, MS (ESI): m / z 274 [M+H] + ).

[0637] [Step 5] Preparation of N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5- (Methylphenyl)-7-methoxy-6-nitroquinazolin-4-amine

[0638] 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylaniline (1.0 equivalent) prepared in step 4 and 4-chloro-7-methoxy-6-nitroquinazoline (1.0 equivalent) were dissolved in sec-butyl alcohol (0.25 M), and then 4M HCl (0.2 equivalent) dissolved in 1,4-dioxane was added thereto, followed by stirring at 90° C. for 30 minutes. After methanol and diethyl ether were added to the reaction mixture, the desired compound was obtained as a yellow solid through a filter (yield: 65%, MS (ESI): m / z 477 [M+H] + ).

[0639] [Step 6] Preparation of N 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5- (Methylphenyl)-7-methoxyquinazoline-4,6-diamine

[0640] N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylphenyl)-7-methoxy-6-nitroquinazolin-4-amine (1.0 equiv.) prepared in step 5 and SnCl2.2H2O (6.0 equiv.) were dissolved in ethyl acetate (0.1 M), and the mixture was stirred at 60°C for 2 hours. Aqueous ammonia solution was added to the reaction mixture, which was then concentrated. The reaction mixture was purified using MPLC (dichloromethane:methanol) to obtain the desired compound as a yellow solid (yield: 64%, MS (ESI): m / z 447 [M+H] + ).

[0641] [Step 7] Preparation of (2-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy- d3) diethyl (5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-1-fluoro-2-oxoethyl)phosphonate

[0642] 2-(Diethoxyphosphoryl)-2-fluoroacetic acid (2.0 equiv.) and HATU (3.0 equiv.) were dissolved in DMF (0.5 M) and then stirred at 50° C. for 30 min. 4 -(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylphenyl)-7-methoxyquinazoline-4,6-diamine (1.0 equivalent) and DIPEA (3.0 equivalent) were added to the mixture, followed by stirring at 50° C. for 1 hour. Ice water was added to the reaction mixture to form a solid, which was then filtered to obtain the desired compound as a yellow solid (yield: 100%, MS (ESI): m / z 643 [M+H] + ).

[0643] [Step 8] Preparation of (R,E / Z)-2-(3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)- 2-(Methoxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-2-fluoro-3-oxoprop-1-ene- tert-Butyl 1-pyrrolidine-1-carboxylate

[0644] The diethyl (2-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-1-fluoro-2-oxoethyl)phosphonate (1.0 equivalent) obtained in step 7 was dissolved in DMF (0.5M), and then (R)-tert-butyl 2-formylpyrrolidine-1-carboxylate (1.5 equivalents) and MgSO4 (1.5 equivalents) were added thereto at 0°C, followed by stirring at room temperature for 1 hour. After water was added to the reaction mixture and the organic matter was extracted with dichloromethane, the remaining water in the collected organic layer was removed with Na2SO4, and the collected organic layer was concentrated. The desired compound obtained as a brown solid was used for the subsequent reaction without further purification (yield: 100%, MS (ESI): m / z 688 [M+H] + ).

[0645] [Step 9] Preparation of (R, E / Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methyl Oxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(pyrrolidin-2-yl)acrylamide

[0646] The (R,E / Z)-tert-butyl 2-(3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)-2-fluoro-3-oxoprop-1-en-1-yl)pyrrolidine-1-carboxylate (1.0 equivalent) obtained in step 8 was dissolved in dichloromethane (0.1 M), and TFA (20.0 equivalent) was added thereto, and the mixture was stirred at room temperature for 1 hour and then concentrated. The concentrated mixture was purified using MPLC (dichloromethane:methanol) to obtain the desired compound as a brown liquid (yield: 100%, MS (ESI): m / z 588 [M+H] + ).

[0647] [Step 10] Preparation of (R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methyl Oxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)propene Amide and (R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methyl (phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide

[0648] (R,E / Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(pyrrolidin-2-yl)acrylamide (1.0 equiv.) obtained in step 9 and 37% formaldehyde (5.0 equiv.) were dissolved in DCE (0.2 M), followed by stirring at room temperature for 1 hour. Sodium triacetoxyborohydride (4.0 equiv.) was added to the mixture, followed by stirring at 80°C for 1 hour. Saturated aqueous NaHCO3 solution and dichloromethane were added to the reaction mixture to extract organic matter, residual water was removed with MgSO4, and the organic layer was concentrated. The reaction mixture was purified using MPLC (dichloromethane:methanol) to obtain the desired compound as a yellow solid. ((R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide - Yield: 11%, MS (ESI): m / z 602 [M+H] + ,((R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide - Yield: 4%, MS (ESI): m / z 602 [M+H] +).

[0649] Preparation of Compounds of Examples 148, 151 and 152

[0650] In a similar manner to the preparation of Example 15, the compounds according to the invention of Examples 148, 151 and 152 were prepared.

[0651] Chemical structural formulas, compound names, and 1 H NMR, MS, yields, HPLC data and purity are summarized in Table 15 below.

[0652] [Table 15]

[0653]

[0654]

[0655] (*: When "*" is shown to the right of a number listed in the last column, the number means NMR purity.)

[0656] Preparation Example 16: Preparation of (R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-(methyl-d3)pyrrolidin-2-yl)acrylamide (Example 155) and (R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-(methyl-d3)pyrrolidin-2-yl)acrylamide (Example 157)

[0657] [Reaction Scheme 18]

[0658]

[0659] (R,E / Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(pyrrolidin-2-yl)acrylamide (1.0 equiv.) and K2CO3 (1.0 equiv.), prepared in a manner similar to that of Example 12, were dissolved in ACN (0.13 M), and iodomethane-d3 (1.0 equiv.) dissolved in ACN (0.5 M) was then added thereto at 0°C, and the mixture was stirred at room temperature for 16 hours. Organic matter was extracted by adding water and ethyl acetate to the reaction mixture, residual water was removed with MgSO4, and the organic layer was concentrated. The reaction mixture was purified using prep-HPLC to obtain the desired compound as a yellow solid. ((R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-(methyl-d3)pyrrolidin-2-yl)acrylamide - Yield: 1%, MS (ESI): m / z 606 [M+H] + ,(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-(methyl-d3)pyrrolidin-2-yl)acrylamide - Yield: 1%, MS (ESI): m / z 606 [M+H] + ).

[0660] Preparation of Compounds of Examples 153, 154 and 156

[0661] In a similar manner to the preparation of Example 16, compounds according to Examples 153, 154 and 156 of the invention were prepared.

[0662] Chemical structural formulas, compound names, and 1 H NMR, MS, yields, HPLC data and purity are summarized in Table 16 below.

[0663] [Table 16]

[0664]

[0665]

[0666]

[0667] (*: When "*" is shown to the right of a number listed in the last column, the number means NMR purity.)

[0668] <Experimental example>

[0669] The example compounds prepared above were evaluated by the following experiments.

[0670] Experimental Example 1. Evaluation of the activity of inhibiting HER2 enzyme

[0671] The biochemical kinase assay for HER2 was performed by Reaction Biology Corp. (San Diego, USA). Example compounds were diluted 3-fold from 10 μM for HER2 enzyme under ATP (10 μM) conditions to measure the 10-dose IC 50 , the results are shown in Table 17 below.

[0672] [Table 17]

[0673] Example HER2 Example HER2 2 A 42 A 8 A 50 A 25 A 54 A 29 A 92 A 30 A 111 A 33 A 128 A

[0674] (A:IC 50 ≤50nM, B:50nM <IC 50 ≤100nM, C:100nM <IC 50 ≤500nM, D:500nM <IC 50 )

[0675] Experimental Example 2. Evaluation of the activity of inhibiting proliferation of BT-474 and N-87 cells

[0676] BT-474 cancer cells were cultured using RPMI-1640 culture medium containing 20% ​​FBS. 48 hours before treating BT-474 cancer cells with the example compounds, BT-474 cancer cells were seeded into a 96-well plate (Corning) with a white transparent bottom at 5000 cells per well. The example compounds were diluted in dimethyl sulfoxide (3-fold dilution, a total of 11 concentrations), and 1 μL was injected for each, so that the final concentration was 0.2nM to 10 μM. In order to measure living cells, after a predetermined time (120 hours) after treatment with the example compounds, the cells were stored at room temperature for 10 minutes using CellTiter-Glo cell viability reagent (Promega), and then the luminescence intensity was measured using a reader (SynergyNeo, Biotek). Each test was repeated three times.

[0677] N-87 cancer cells were cultured using RPMI-1640 culture medium containing 10% FBS. 24 hours before treating N-87 cancer cells with the example compounds, N-87 cancer cells were seeded into a 96-well plate (Corning) with a white transparent bottom at 5000 cells per well. The example compounds were diluted in dimethyl sulfoxide (5-fold dilution, 11 concentrations in total), and 0.5 μL was injected for each, making the final concentration 0.5 pM to 5 μM. In order to measure living cells, 72 hours after the example compound treatment, the cells were stored at room temperature for 10 minutes using CellTiter-Glo cell viability reagent (Promega), and then the luminescence intensity was measured using a reader (SynergyNeo, Biotek).

[0678] The result value was calculated as the cell growth rate (%) compared with the control group. GraphPad Prism version 8.0 program was used to draw graphs and calculate GI 50 The results are shown in Table 18 below.

[0679] [Table 18]

[0680]

[0681] (A:GI 50 ≤50nM, B:50nM <GI 50 ≤100nM, C:100nM <GI 50 ≤500nM, D:500nM <GI 50 )

[0682] Experimental Example 3. Evaluation of the activity of inhibiting the proliferation of transduced Ba / F3 cells

[0683] Transduced Ba / F3 cells were cultured by adding 1 μg / mL of puromycin (Invitrogen) to a medium (RPMI-1640) containing 10% fetal bovine serum (FBS). 3000 Ba / F3 HER2 WT cells were seeded into a white transparent bottom 96-well plate (Corning) 24 hours before treating Ba / F3 HER2 WT cells with the example compounds. For Ba / F3 HER2 L755S, Ba / F3 HER2 L755P, Ba / F3 HER2T862A and Ba / F3 HER2 L869R / T798I cells, 5000 cells of each were seeded into a white transparent bottom 96-well plate (Corning) 24 hours before treating cells with the compounds. The example compounds were diluted in dimethyl sulfoxide (3-fold dilution, a total of 11 concentrations), and 0.5 μL of each was injected to a final concentration of 0.2 nM to 10 μM. To measure viable cells, 72 hours after treatment with the example compounds, the cells were stored at room temperature for 10 minutes using CellTiter-Glo cell viability reagent (Promega), and then the luminescence intensity was measured using a reader (SynergyNeo, Biotek). Each test was repeated twice.

[0684] The result values ​​were calculated as the cell growth rate (%) compared with the control group, and the GI was calculated using software (GraphPad Prism version 8.0) 50 The results are shown in Table 19 below.

[0685] [Table 19]

[0686]

[0687] (A:GI 50 ≤50nM, B:50nM <GI 50 ≤100nM, C:100nM <GI 50 ≤500nM, D:500 <GI 50 nM)

[0688] The results of the experimental examples confirmed that the example compounds of the present invention exhibited high inhibitory activity against HER2 and inhibited the proliferation of HER2-activated cells.

[0689] Although the present invention has been described in detail with reference to preferred embodiments and experimental examples, the scope of the present invention is not limited to specific example compounds, but should be interpreted by the appended claims. In addition, it will be appreciated by those skilled in the art that many modifications and variations can be made without departing from the scope of the present invention.

Claims

1. A compound represented by formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: in: Ring A is aromatic or non-aromatic C 6-12 A carbocyclic ring or a 5- to 12-membered heterocyclic ring, wherein Ring A has or does not have a ring selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, -CN, -NR A1 R A2 、-NO2、-OR A3 、-C(=O)-NR A1 R A2 、-C(=O)-OR A3 、-NH-C(=O)-(C 1-6 alkyl), =O, halogen and one or more substituents of 5- to 6-membered heteroaryl, wherein the heteroaryl is unsubstituted or substituted with C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy or halogen substitution; R A1 To R A3 Each independently is H or C 1-6 alkyl; X1 is C 1-6 Alkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Haloalkyl, C 1-6 Haloalkyl, C 3-12 Cycloalkyl or 3 to 12 membered heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are unsubstituted or replaced by C 1-6 Alkyl or C 1-6 haloalkyl substitution; X2 is H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, -CN, -NR B1 R B2 、-NO2、-OR B3 or halogen; R B1 To R B3 Each independently is H or C 1-6 alkyl; Y1 is CR1 or N; Y2 is CR2, C(-LZ) or N; Y3 is CR3 or N; R1 is H, C 1-6 Alkyl, C 1-6 Alkylamino or -CN; R2 is H, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 1-6 Haloalkyl, -CN, -NH2 or halogen; R3 is H, halogen, -OR4 or -NR5R6, or R3 and L are connected to form a 5- to 6-membered heterocyclic ring; R4 is H, C 1-6 Alkyl, -(CH2)nO-(C 1-6 Alkyl), C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, -(CH2)n-(C 3-6 cycloalkyl), 3 to 6 membered heterocycloalkyl or -(CH2)n-(3 to 6 membered heterocycloalkyl), wherein the cycloalkyl and heterocycloalkyl have or do not have a member selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, -CN, -NR C1 R C2 、-NO2、-OR C3 and one or more substituents of halogen; n is each independently an integer from 1 to 4; R C1 To R C3 Each independently is H or C 1-6 alkyl; R5 and R6 are each independently H or C 1-6 alkyl, or R5 and R6 are connected to each other to form a 3- to 12-membered heterocyclic ring, wherein the heterocyclic ring is unsubstituted or replaced by C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, -CN, -NR D1 R D2 、-NO2、-OR D3 , halogen or 3- to 6-membered heterocycloalkyl; R D1 To R D3 Each independently is H or C 1-6 alkyl; L is -NH-, Or L is connected to R3 to form a 5- to 6-membered heterocyclic ring, wherein ring B is a 3- to 8-membered heterocyclic ring containing a nitrogen atom in the ring, and ring B may or may not have a member selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 1-6 One or more substituents selected from haloalkyl, -OH and halogen; Z is Z1 is H, C 1-6 Alkyl, C 1-6 haloalkyl, -CN, halogen or 5- to 6-membered heteroaryl; Z2 and Z3 are each independently H, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkylamino, C 1-6 Haloalkyl, halogen, C 3-12 Cycloalkyl, 3- to 12-membered heterocycloalkyl, -(CH2)m-(C 1-6 alkylamino), -(CH2)m-(C 3-12 -(CH2)m-(3 to 12-membered heterocycloalkyl) or -(CH2)m-NH-(3 to 12-membered heterocycloalkyl), wherein -CH2-, the cycloalkyl and heterocycloalkyl may or may not have a member selected from C 1-6 Alkyl, deuterated C 1-6 Alkyl, deuterated C 1-6 Haloalkyl, -OH, =O, -C(=O)-(C 1-6 alkoxy) and one or more substituents of 3 to 6-membered heterocycloalkyl; m is each independently an integer from 1 to 4; and The heterocyclic ring, heteroaryl group and heterocycloalkyl group each independently contain at least one heteroatom selected from N, S and O.

2. The compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Ring A is aromatic C 6-12 A carbocyclic or aromatic or non-aromatic 5- to 12-membered heterocyclic ring, wherein Ring A has or does not have a ring selected from C 1-6 Alkyl, -NR A1 R A2 、-OR A3 、-C(=O)-NR A1 R A2 、-C(=O)-OR A3 、-NH-C(=O)-(C 1-6 alkyl), =O, halogen and one or more substituents of 5- to 6-membered heteroaryl, wherein the heteroaryl is unsubstituted or substituted with C 1-6 Alkyl, C 1-6 Alkoxy or halogen substitution; R A1 To R A3 Each independently is H or C 1-6 alkyl; X1 is C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-12 Cycloalkyl or 3 to 12 membered heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are unsubstituted or replaced by C 1-6 Alkyl or C 1-6 Haloalkyl substitution; X2 is H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, -NR B1 R B2 or halogen; R B1 and R B2 Each independently is C 1-6 Alkyl; and The heterocyclic ring, heteroaryl group and heterocycloalkyl group each independently contain at least one heteroatom selected from N, S and O.

3. The compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Y1 is CR1 or N; Y2 is CR2, C(-LZ) or N; Y3 is CR3 or N; R1 is H or -CN; R2 is H or halogen; R3 is H, halogen, -OR4 or -NR5R6, or R3 and L are connected to form a 5- to 6-membered heterocyclic ring; R4 is C 1-6 Alkyl, -(CH2)nO-(C 1-6 Alkyl), C 1-6 haloalkyl, 3 to 6 membered heterocycloalkyl or -(CH2)n-(3 to 6 membered heterocycloalkyl), wherein the cycloalkyl and heterocycloalkyl have or do not have a member selected from C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, -CN, -NR C1 R C2 、-NO2、-OR C3 and one or more substituents of halogen; n is each independently an integer from 1 to 4; R C1 To R C3 Each independently is H or C 1-6 alkyl; R5 and R6 are each independently H or C 1-6 alkyl, or R5 and R6 are connected to each other to form a 3- to 12-membered heterocyclic ring, wherein the heterocyclic ring is a 4- to 6-membered monocyclic ring or a 5- to 12-membered spirocyclic ring, and the heterocyclic ring is unsubstituted or substituted with halogen or a 3- to 6-membered heterocycloalkyl; and The heterocyclic ring and heterocycloalkyl group each independently contain at least one heteroatom selected from N, S and O.

4. The compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: L is -NH-, Or L is connected to R3 to form a 5- to 6-membered heterocyclic ring, wherein ring B is a 3- to 8-membered heterocyclic ring containing a nitrogen atom in the ring, and ring B may or may not have a member selected from C 1-6 Alkyl, C 1-6 one or more substituents of haloalkyl and halogen; Z is Z1 is H, -CN, halogen or 5- to 6-membered heteroaryl; Z2 and Z3 are each independently H, C 1-6 Alkyl, C 1-6 Alkylamino, halogen, C 3-12 Cycloalkyl, 3- to 12-membered heterocycloalkyl, -(CH2)m-(C 1-6 alkylamino), -(CH2)m-(C 3-12 -(CH2)m-(3 to 12-membered heterocycloalkyl) or -(CH2)m-NH-(3 to 12-membered heterocycloalkyl), wherein -CH2-, the cycloalkyl and heterocycloalkyl may or may not have a member selected from C 1-6 Alkyl, deuterated C 1-6 Alkyl, -OH, =O, -C(=O)-(C 1-6 alkoxy) and one or more substituents of 3 to 6-membered heterocycloalkyl; m is each independently an integer from 1 to 4; and The heterocyclic ring, heteroaryl group and heterocycloalkyl group each independently contain at least one heteroatom selected from N, S and O.

5. The compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Ring A is A1 to A9 are each independently CH or N; B1 to B3 are each independently CH2, NH, O or S; wherein ring A has or does not have a member selected from C 1-6 Alkyl, -NR A1 R A2 、-OR A3 、-C(=O)-NR A1 R A2 、-C(=O)-OR A3 、-NH-C(=O)-(C 1-6 alkyl), =O, halogen and one or more substituents of 5- to 6-membered heteroaryl, wherein the heteroaryl is unsubstituted or substituted with C 1-6 Alkyl, C 1-6 Alkoxy or halogen substitution; R A1 To R A3 Each independently is H or C 1-6 Alkyl; and The heteroaryl group contains at least one heteroatom selected from N, S and O.

6. The compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: L is -NH-, The heterocyclic ring containing N may or may not be selected from C 1-6 Alkyl, C 1-6 one or more substituents of haloalkyl and halogen, or L is linked to R3 to form a 5- to 6-membered heterocyclic ring containing N; and The heterocyclic ring containing N may contain at least one heteroatom selected from S and O in addition to N.

7. The compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound is selected from the following group: 1>1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one; 2> 1-(4-((4-((5-chloro-4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one; 3> 1-(4-((4-((5-chloro-2-methoxy-4-(pyridin-2-yloxy)phenyl)amino)-7-methoxyquinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one; 4> 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-methyl-2-((1-methylazetidin-3-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)amino)piperidin-1-yl)prop-2-en-1-one; 5> 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one; 6> 1-(4-((4-((5-chloro-4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-3-fluoropiperidin-1-yl)prop-2-en-1-one; 7> 1-(4-((4-((4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one; 8> 1-(4-((4-((5-chloro-4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one; 9> 1-(4-((4-((4-((1-(5-fluoro-6-methylpyridin-3-yl)-1H-pyrazol-3-yl)oxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one; 10> 1-(4-((7-methoxy-4-((2-methoxy-4-((1-(2-methoxypyrimidin-5-yl)-1H-pyrazol-3-yl)oxy)phenyl)amino)quinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one; 11>1-(4-((4-((5-chloro-2-methoxy-4-(3-methoxyphenoxy)phenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one; 12> 4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinoline-3-carbonitrile; 13> methyl 4-(4-((6-((1-acryloylpiperidin-4-yl)oxy)-7-methoxyquinazolin-4-yl)amino)-5-methoxy-2-methylphenoxy)benzoate; 14> 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)-2-chloro-2-fluoroethan-1-one; 15> 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-5-yl)oxy)-3,3-difluoropiperidin-1-yl)prop-2-en-1-one; 16> 1-(3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-5-yl)oxy)-4,4-difluoropiperidin-1-yl)prop-2-en-1-one; 17> 1-(4-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one; 18> 1-(5-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-yl)prop-2-en-1-one; 19> 1-(3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-1-yl)prop-2-en-1-one; 20>1-(3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pyrrolidin-1-yl)prop-2-en-1-one; 21>1-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazolin-6-yl)prop-2-en-1-one; 22> N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(4-morpholinopiperidin-1-yl)quinazolin-6-yl)acrylamide; 23> N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-morpholinequinazolin-6-yl)acrylamide; 24> N-(4-((5-chloro-2-methoxy-4-(pyridin-2-yloxy)phenyl)amino)-7-methoxyquinazolin-6-yl)acrylamide; 25> (E)-N-(4-((5-chloro-4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-4-(dimethylamino)but-2-enamide; 26>(E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-5-chloroquinazolin-6-yl)-4-(dimethylamino)but-2-enamide; 27> 1-(4-(8-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperazin-1-yl)prop-2-en-1-one; 28> N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)but-2-ynamide; 29>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 30>(R,E)-N-(4-((5-chloro-4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 31>(R,E)-N-(4-((5-chloro-4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(pyrrolidin-2-yl)acrylamide; 32>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 33>(R,E)-N-(4-((5-chloro-2-methoxy-4-(pyridin-2-yloxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 34>(R,E)-N-(8-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 35> (E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(2-methyl-2-azabicyclo[3.1.0]hexan-3-yl)acrylamide; 36>(E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpiperidin-2-yl)acrylamide; 37>(S,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 38> (E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino)but-2-enamide; 39> (E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-4-(5-hydroxyhexahydrocyclopenta[c]pyrrol-2(1H)-yl)but-2-enamide; 40>(E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-4-(2-oxa-6-azaspiro[3.3]heptane-6-yl)but-2-enamide; 41>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 42>(R,E)-N-(4-((5-chloro-4-(3-fluorophenoxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 43>(Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 44>(S,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 45>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methyl-5-oxopyrrolidin-2-yl)acrylamide; 46>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 47>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 48>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 49>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 50>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 51>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 52>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-ethylpyrrolidin-2-yl)-2-fluoroacrylamide; 53>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-(trifluoromethyl)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 54>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-(trifluoromethyl)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 55>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((1-methyl-1H-benzo[d]imidazol-6-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 56>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 57> (R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 58>(R,Z)-N-(4-((5-chloro-2-methoxy-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 59>(R,E)-N-(4-((5-chloro-2-methoxy-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 60>(R,E)-2-Fluoro-N-(4-((5-fluoro-2-methoxy-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 61>(R,Z)-2-Fluoro-N-(4-((5-fluoro-2-methoxy-4-((1-methyl-1H-benzo[d]imidazol-5-yl)oxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 62>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(quinoxalin-6-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 63>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(quinoxalin-6-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 64>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(naphthalen-2-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 65>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(naphthalen-2-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 66>(R,E)-N-(4-((4-(Benzo[d]oxazol-6-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 67> (R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((2-methylbenzo[d]oxazol-5-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 68>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((2-methylbenzo[d]oxazol-5-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 69>(E)-2-Fluoro-N-(4-((4-((2-hydroxy-2,3-dihydrobenzo[d]oxazol-5-yl)oxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-((R)-1-methylpyrrolidin-2-yl)acrylamide; 70>(Z)-2-Fluoro-N-(4-((4-((2-hydroxy-2,3-dihydrobenzo[d]oxazol-5-yl)oxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-((R)-1-methylpyrrolidin-2-yl)acrylamide; 71>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((1-methyl-2-oxo-1,2-dihydropyridin-4-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 72>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 73>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 74>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-phenoxyphenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 75>(R,E)-2-fluoro-N-(4-((4-(imidazo[1,2-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 76>(R,Z)-2-fluoro-N-(4-((4-(imidazo[1,2-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 77>(R,E)-2-fluoro-N-(4-((4-(imidazo[1,2-c]pyrimidin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 78>(R,E)-N-(8-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 79>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(pyrazolo[1,5-a]pyrimidin-6-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 80>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(pyrazolo[1,5-a]pyrimidin-6-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 81>(R,E)-N-(4-((4-(Benzo[d]thiazol-6-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 82>(R,Z)-N-(4-((4-(Benzo[d]thiazol-6-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 83>(R,Z)-N-(4-((4-(Benzo[d]thiazol-5-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 84>(R,E)-N-(4-((4-(Benzo[d]thiazol-5-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 85>(R,E)-N-(4-((4-(Benzo[d][1,3]dioxol-5-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 86>(R,Z)-N-(4-((4-(Benzo[d][1,3]dioxol-5-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 87>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(quinolin-7-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 88>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-(quinolin-7-yloxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 89>(R,E)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((1-methyl-1H-indazol-6-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 90>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((1-methyl-1H-indazol-6-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 91>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 92>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 93>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 94>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(2-methoxyethoxy)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 95>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(2-methoxyethoxy)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 96>(E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-3-((R)-1-methylpyrrolidin-2-yl)acrylamide; 97>(Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-2-fluoro-3-((R)-1-methylpyrrolidin-2-yl)acrylamide; 98>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(difluoromethoxy)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 99>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(difluoromethoxy)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 100>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(2-morpholinethoxy)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 101>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(2-morpholinethoxy)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 102>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-fluoroquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 103>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-fluoroquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 104>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-ethoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 105>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-methyl-2-(trifluoromethoxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 106>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-cyclopropyloxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 107>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-cyclopropyloxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 108>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-methyl-2-(oxetan-3-yloxy)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 109>(R,E)-tert-butyl 2-(3-((4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(oxetan-3-yloxy)phenyl)amino)-7-methoxyquinazolin-6-yl)amino)-2-fluoro-3-oxoprop-1-en-1-yl)pyrrolidine-1-carboxylate; 110>(E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-((3R)-hexahydro-1H-pyrrolizin-3-yl)acrylamide; 111>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 112>(S,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 113>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(4,4-difluoropiperidin-1-yl)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 114>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(3,3-difluoroazetidin-1-yl)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 115>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(4-morpholinopiperidin-1-yl)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 116>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(2-oxa-6-azaspiro[3.3]heptane-6-yl)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 117> N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(2-oxa-6-azaspiro[3.3]heptane-6-yl)quinazolin-6-yl)acrylamide; 118>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-(methylamino)quinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 119>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-6-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 120>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 121>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-3-(pyrrolidin-2-yl)acrylamide; 122>(S,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 123>(R,E)-N-(4-((4-(4-(dimethylamino)phenoxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 124>(R,E)-methyl 4-(4-((6-(2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamido)-7-methoxyquinazolin-4-yl)amino)-5-methoxy-2-methylphenoxy)benzoate; 125>(R,Z)-4-(4-((6-(2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide)-7-methoxyquinazolin-4-yl)amino)-5-methoxy-2-methylphenoxy)-N,N-dimethylbenzamide; 126>(R,E)-4-(4-((6-(2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamido)-7-methoxyquinazolin-4-yl)amino)-5-methoxy-2-methylphenoxy)-N,N-dimethylbenzamide; 127>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-(dimethylamino)-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 128>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 129>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyphenyl)amino)-7-ethoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 130>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyphenyl)amino)-7-morpholinoquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 131>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpiperidin-2-yl)acrylamide; 132>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 133>(R,Z)-N-(4-((4-(3-acetamidophenoxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 134>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(pyrrolidin-2-yl)acrylamide; 135>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(pyrrolidin-2-yl)acrylamide; 136>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-chloro-3-(1-methylpyrrolidin-2-yl)acrylamide; 137>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-cyclopropyl-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 138>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-cyclopropyl-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 139>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 140>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-bromo-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 141>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-5-chloroquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 142>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-5-chloroquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 143>(R,Z)-2-Fluoro-N-(7-methoxy-4-((2-methoxy-5-methyl-4-((5-methyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)oxy)phenyl)amino)quinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 144>(Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-cyano-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enamide; 145>(E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enamide; 146>(E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-4,4-dimethylpent-2-enamide; 147> N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-(1H-pyrazol-1-yl)acrylamide; 148>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide; 149>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 150>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-(methoxy-d3)-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 151>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-(methoxy-d3)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 152>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-(methoxy-d3)phenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-methylpyrrolidin-2-yl)acrylamide; 153>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-3-(1-(methyl-d3)pyrrolidin-2-yl)acrylamide; 154>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-methoxy-5-methylphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-(methyl-d3)pyrrolidin-2-yl)acrylamide; 155>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-(methyl-d3)pyrrolidin-2-yl)acrylamide; 156>(R,Z)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-chloro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-(methyl-d3)pyrrolidin-2-yl)acrylamide; and 157>(R,E)-N-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-5-fluoro-2-methoxyphenyl)amino)-7-methoxyquinazolin-6-yl)-2-fluoro-3-(1-(methyl-d3)pyrrolidin-2-yl)acrylamide.

8. A pharmaceutical composition for treating or preventing a disease associated with human epidermal growth factor receptor 2 (HER2), the pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 7 or a pharmaceutically acceptable salt or stereoisomer thereof as an active ingredient.

9. The pharmaceutical composition according to claim 8, wherein The HER2-related diseases include cancer.

10. The pharmaceutical composition according to claim 8, wherein The HER2-related disease is selected from pseudomyxoma, intrahepatic bile duct cancer, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphocytic leukemia, basal cell carcinoma, ovarian epithelial cancer, ovarian germ cell cancer, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colorectal cancer, chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampulla of Vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, nasal cancer, non-small cell lung cancer, tongue cancer, astrocytoma, small cell lung cancer, childhood brain cancer, childhood lymphoma, childhood leukemia, small intestine cancer, meningioma, esophageal carcinoma, glioma, renal pelvis cancer, kidney cancer, heart cancer, duodenal cancer, malignant soft tissue tumor, malignant bone cancer, malignant lymphoma, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureter cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, gastric cancer, gastric carcinoid, gastrointestinal stromal cancer, Wilms' tumor, breast cancer, sarcoma, penile cancer, pharyngeal cancer, gestational choriocarcinoma, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, rectal cancer, rectal carcinoid, vaginal cancer, spinal cord cancer, vestibular schwannoma, pancreatic cancer, salivary gland cancer, Kaposi's sarcoma, Paget's disease, tonsil cancer, squamous cell carcinoma, lung adenocarcinoma, lung cancer, lung squamous cell carcinoma, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleural cancer, blood cancer and thymus cancer.

11. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 7 or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable additive.

12. Use of a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to any one of claims 1 to 7 for treating or preventing HER2-related diseases.

13. Use of a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof according to any one of claims 1 to 7 in the preparation of a medicament for treating or preventing HER2-related diseases.

14. A method for treating or preventing a HER2-related disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) according to any one of claims 1 to 7 or a pharmaceutically acceptable salt or stereoisomer thereof.

15. A method for treating or preventing a disease selected from pseudomyxoma, intrahepatic bile duct carcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphocytic leukemia, basal cell carcinoma, ovarian epithelial cancer, ovarian germ cell cancer, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colorectal cancer , chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampulla of Vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, nasal cancer, non-small cell lung cancer, tongue cancer, astrocytoma, small cell lung cancer, childhood brain cancer, childhood lymphoma, childhood leukemia, small intestine cancer, meningioma, esophageal cancer, glioma, renal pelvis cancer, kidney cancer, heart cancer, duodenal cancer, malignant soft tissue tumors, malignant bone A method for treating at least one of cancer, malignant lymphoma, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureteral cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, gastric cancer, gastric carcinoid, gastrointestinal stromal cancer, Wilms' tumor, breast cancer, sarcoma, penile cancer, pharyngeal cancer, gestational choriocarcinoma, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, rectal cancer, rectal carcinoid, vaginal cancer, spinal cord cancer, vestibular schwannoma, pancreatic cancer, salivary gland cancer, Kaposi's sarcoma, Paget's disease, tonsil cancer, squamous cell carcinoma, lung adenocarcinoma, lung cancer, lung squamous cell carcinoma, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleural cancer, blood cancer and thymic cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) according to any one of claims 1 to 7 or a pharmaceutically acceptable salt or stereoisomer thereof.